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ABSTRACT

PHARMACEUTICAL QUALITY PERFORMANCE
OF FOLIC ACID SUPPLEMENTS
Islam Rasem Younis
The vitamin folic acid has received considerable attention in the 1990s
because of its preventative role against diseases such as neural tube defects,
cardiovascular diseases, and psychiatric illness.
A primary concern is the pharmaceutical quality, potency, and efficacy of
commercially available folic acid products and label claims. The results showed
that there has been significant progress since the 1990’s in the improved quality of
commercially available folic acid products in meeting USP standards.
Products were also tested in physiologically relevant solutions. Most
notably, all the tested products failed to release more than 75% of the active
ingredient in 60 minutes in simulated gastric fluid. While some excipient-related
factors were preliminarily considered, it was ultimately hypothesized that the
failure may be related to the folic acid pH-solubility profile, confirmed by the
increased release rate of folic acid from buffered tablets compared with nonbuffered tablets, when constant surface area dissolution was maintained.
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Chapter I
Clinical Importance of Folic Acid

Folate, historically known as Will's factor and vitamin M, was isolated in
an unknown chemical form in 1941. The term folate refers to the many different
naturally occurring forms of the compound, all of which are made up of a
pteridine ring, p-aminobenzoic acid, and one to six glutamic acids moieties
(Figure 1). Dietary folate is in the chemical form of pteroylpolyglutamate, and, in
order for it to be absorbed, it must be cleaved or hydrolyzed in the small intestine
to the monoglutamate. The chemical form of the pharmaceutical folate is
pteroylglutamate, which does not need to be hydrolyzed in order to be absorbed.
Therefore, synthetic folic acid supplements can provide better bioavailability than
folate from natural sources (1, 2).
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Figure1. Folic Acid Structure.
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Folic acid is a water-soluble vitamin that has been used to treat macrocytic
anemia without neurologic disease (3). Folate deficiency is a common finding in:
• The elderly.
• Alcoholics.
• The poor.
• Rheumatoid arthritis patients receiving long-term methotrexate therapy.
• AIDS patients receiving sulfa drugs or pentamidine pnemocystis
prophylaxis.
• Dialysis patients, since folic acid is removed from the body during dialysis
in patients with chronic renal failure.
Folic acid deficiency may be caused by a variety of factors, including:
• Malabsorption.
• Malnutrition.
• Inadequate utilization.
• Increased requirement by the body for folic acid.
• Increased excretion or destruction.
Both dietary and pharmaceutical folates are converted to
5-methyltetrahydrofolate (5-CH3-THF), which is the primary circulatory folate in
serum, red blood cells (RBC), and cerebrospinal fluid (4, 5). The liver is the
primary storage depot for 5-CH3-THF, which donates its methyl group in
conjunction with the cofactor vitamin B12 to homocysteine, resulting in the
formation of methionine and tetrahydrofolate (THF) (Figure 2). Methionine is the
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Figure 2. Homocysteine-methionine metabolism.
(Adapted from reference 6)
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precursor to S-adenosylmethionine (SAM), which is considered to be the universal
methyl-group donor that is involved in many metabolic reactions (4, 5).
Deficiencies of both vitamin B12 and folate decrease methionine formation
from homocysteine and may result in decreased SAM. It should be noted that
methionine is available in the diet. During vitamin B12 deficiency alone, folate is
trapped as 5-CH3-THF, because only the enzyme methionine synthase, along with
vitamin B12, can convert it to THF. This is called a functional folate deficiency,
even though blood folate levels may be normal. Hyperhomocystinemia occurs
with a deficiency of either folate or B12. Elevated homocysteine levels occur in
mothers of children with neural tube defects, and in patients with peripheral
vascular disease, stroke, coronary artery disease (CAD), myocardial infarction,
isolated systolic hypertension, and thrombosis.
In the body, homocysteine is metabolized by two pathways (7):
1. Transsulfuration into cysteine which is then excreted in the urine.
2. Remethylation back to methionine which may be accomplished by two
routes:
• Combining betaine and homocysteine in the presence of betainehomocysteine methyl transferase to make methionine and dimethyl glycine.
•

The second and the most important route in vivo involves the conversion
of SAM and homocysteine to methionine and tetrahydrofolate by
methionine synthase.

Folate obtained from a pharmaceutical preparation is the most bioavailable,
because 10% to 50% of dietary folate is lost in the cooking process (2). Thus, food
enriched with folate may have limited amounts available. In 1998, the Institute of
Medicine report described a new term called the Dietary Folate Equivalent (DFE),
where one DFE is equal to 1 µg of food folate, 0.5 µg of supplemental folic acid
4

(pharmaceutical preparations), and 0.6 µg of food fortified with folate (2). This
reinforced the fact that pharmaceutical preparations containing folic acid are more
bioavailable than food folate. However, it did not make the pharmaceutical
preparation a substitute for a balanced diet containing folate. Importantly, different
over-the-counter pharmaceutical preparations have different potency and
dissolution characteristics (8). Therefore, it cannot be assumed that all
pharmaceutical preparations have the same bioavailability of folic acid.
The vitamin folic acid has received considerable attention in the 1990s
because of its disease preventative role. The most significant literature exists in the
area of periconceptional use of the vitamin to decrease the risk of neural tube
defects (NTDs) such as spina bifida. It has also been suggested that folic acid may
be effective in decreasing certain risks of cardiovascular disease and psychiatric
illness, most notably dementia (6).
1. Prevention of neural tube defect.
The technical names of the two major neural tube birth defects reduced by
adequate folate intake are anencephaly and spina bifida. Babies with anencephaly
do not develop a brain and are stillborn or die shortly after birth. Those with spina
bifida have a defect of the spinal column that can result in varying degrees of
handicap, from mild and hardly noticeable cases of scoliosis (a curvature of the
spine) to paralysis and bladder or bowel incontinence (3). With proper medical
treatment, most babies born with spina bifida can survive to adulthood. However,
they may require leg braces, crutches, and other devices to help them walk, and
they may have learning disabilities. About 30 percent have slight to severe mental
retardation.
In the developing fetus, the neural tube closes early in pregnancy at 23 to
27 days after conception, a time when many women do not realize that they are

5

pregnant. Each year in the United States, approximately 4000 pregnancies result in
neural tube defects such as spina bifida or encephalopathy (9). Approximately
40% of the pregnancies in the United States are unplanned (9). In 1992, the U.S.
Public Health Service, joined in 1993 by the American College of Obstetricians
and Gynecologists and the American Academy of Pediatrics Committee on
Genetics, recommended that all women of childbearing age consume 400 µg of
folate daily from food or supplements. These recommendations effectively
overrode the Recommended Dietary Allowance (RDA) of 180 µg daily set in 1989
(reduced from 400 µg daily established in 1968) (3, 9).
Numerous studies have demonstrated the association between levels of
homocysteine and neural tube defects and other congenital defects (8). Many
studies have shown that folic acid supplementation in early pregnancy markedly
reduces the risk of neural tube defects (11). A 72% protective effect of folic acid
against neural tube defects was obtained in a study of 1817 women at high risk of
having pregnancies with neural tube defects (12). Neural tube defects risk declined
markedly with modest increase of total folate in early pregnancy (11). Women
with previously affected offspring who intend to become pregnant should take
daily supplementation containing 0.4 mg of folic acid in the preconception period
to reduce the risk of reoccurrence of neural tube defects (1). Because of the
established correlation between sufficient folic acid levels and healthy fetal
development, and subsequent recent recommendations for folic acid
supplementation, the pharmaceutical quality of commercially available folic acid
supplements becomes of interest to public health.
2. Prevention of heart disease.
Multiple prospective and case-control studies have shown that a moderately
elevated plasma homocysteine concentration is an independent risk factor for
atherothrombotic vascular disease (13). High plasma homocysteine concentration
6

is an independent risk factor for left arterial thrombus formation in patients with
stroke caused by nonvascular atrial fibrillation (14). Prospective studies have
shown that elevated plasma homocysteine concentrations increased the risk of
cardiovascular disease by about two fold (15).
Lowering homocysteine levels in plasma would save lives from the disease
of stroke in the middle aged and the elderly (16). Treatment is most conveniently
administered as a folic acid supplement (400-1000 µg) and a high potency
multivitamin that contains at least 400 µg of folate (17). Folic acid may be used to
reduce homocysteine concentration in patients with coronary artery disease, either
alone or combined with other B vitamins (18). Intake of folic acid and vitamin B6
above 180 µg per day may be important in the primary prevention of coronary
heart disease among women (19). Folic acid and vitamins B6 and B12 are the
mainstay in hyperhomocystenemia therapy. Folic acid, among other drugs and
protective procedures, should be utilized as an agent for reducing cardiovascular
risk in diabetic patients (20).
3. Prevention of colon cancer.
Colorectal cancer is the second most common cause of cancer-related death
in both men and women. Epidemiological studies have suggested that a
diminished folate status is associated with increased risk of colon cancer (21). The
results of animal studies generally support this epidemiologic observation and, in
addition, provide strong evidence for a causal relation between folate status and
colorectal carcinogenesis (22). Folate levels may be inversely related to colorectal
cancer risk, possibly in combination with low methionine and high alcohol
consumption (23).
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4. Antioxidant efficiency.
In a study dealing with the activity of various vitamins against the radicalmediated oxidative damage in human whole blood, the antioxidant activity of
several lipid- and water-soluble vitamins has been assessed by biological assay
and through two chemical methods. Antioxidant activities were observed for folic
acid and pyridoxine, compared to ascorbic acid. The effectiveness of folic acid
was almost three times as high as vitamin C (24).
5. Prevention of gastric and gastrointestinal cancers.
In a randomized, double blind, placebo controlled trial, a total of 216
patients with atrophic gastritis were randomly assigned in order to evaluate the
role of folic acid in the chemoprevention of gastric and other gastrointestinal
cancers. Folic acid displayed a highly significant decrease in the occurrence of and
lowered the risk for, gastrointestinal cancers. The use of folic acid led to obvious
improvement of gastric mucosal lesions, atrophy, inflammation, and pre-cancerous
states. The trial revealed the interventional effect of folic acid on the development
of gastrointestinal cancers. Also, folic acid may be used to treat atrophic gastritis
by preventing or reversing precancerous lesions (25).
6. Risk of low birth weight.
Folic acid-iron daily supplements reduced the percentage of low birth
weight babies from 43 % to 34 % in 4926 pregnant women and 4130 live born
infants in a rural community in southeastern Nepal. Folic acid-iron and
micronutrients (vitamins and minerals) increased head and chest circumference of
babies, but not length. Antenatal folic acid-iron supplements modestly reduced the
risk of low birth weight. Multiple micronutrients seemed to confer no additional
benefit over folic acid- iron in reducing this risk (26).
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7. Risk of breast cancer.
In several epidemiologic investigations, folate intake has appeared to
reduce the elevated risk of breast cancer associated with moderate alcohol
consumption. Higher plasma levels of folate and possibly vitamin B6 may reduce
the risk of developing breast cancer. Achieving adequate circulating levels of
folate may be particularly important for women at higher risk of developing breast
cancer because of higher alcohol consumption (27).
8. Prevention of mood and cognitive disorders.
In neonates, infants, children, and adolescents, inborn errors of folate
transport and metabolism are associated with a variety of overlapping syndromes
that are influenced by the age of clinical presentation.
In adult patients presenting with anemias due to folate deficiency,
approximately two thirds have neuropsychiatric disorders which overlap
considerably with those associated with anemia due to vitamin B-12 deficiency.
The degree of anemia is poorly correlated with the presence of neuropsychiatric
disorders, but, if these anemias were left untreated, nearly all patients would
eventually develop neuropsychiatric complications (6).
Hyperhomocystenemia is an independent risk factor for homocysteine
metabolism and cognitive function, from mild cognitive decline (age-related
memory loss) to vascular dementia and Alzheimer’s disease (28). The association
of folate deficiency, as reflected by low concentrations of folate in serum, red
cells, and cerebrospinal fluid and raised plasma concentrations of homocysteine,
with depression and dementia has been confirmed in epileptic, neurological,
psychiatric, geriatric and psychogeriatric patients and is supported by
neuropsychological, neuropathological, and neurochemical studies. Some of the
deficiency may be related to aging, some may be secondary to mental illness, and
9

some primary. But whether it is primary or secondary, open and controlled
treatment studies confirm an aetiological link with specific effects of the vitamin
on mood, drive, initiative, alertness, concentration, psychomotor speed, and social
activity. These observations are reinforced by cognitive studies in otherwise
healthy subjects, suggesting that low folate levels are associated with patterns of
impairment also found in aging (6).
Within the wide spectrum of depressive disorders, a subgroup has been
identified in which folate and related methylation processes are involved. With
respect to dementia, there is evidence that folate deficiency may contribute to the
cognitive impairment of the aging brain, sometimes leading to reversible dementia
but also increasing the risk of Alzheimer's disease and vascular dementia, perhaps
by methylation related processes or by homocysteine mediated vascular or
neurotoxic mechanisms. It is well known that depression may be a precursor of
dementia in a range of neuropsychiatric syndromes (6).
A significant correlation has been found between risk of Alzheimer’s
disease and high plasma levels of homocysteine, as well as low levels of folic acid,
and vitamins B6 and B12. Providing the nutritional cofactors for proper
functioning of the methionine cycle may improve methylation and protect the
brain from damage (28). It was shown that dietary restriction and supplementation
with folic acid can reduce neuronal damage and improve behavioral outcome in a
mouse model of Alzheimer disease and Parkinson disease (29). A high dose of
folic acid and vitamins B6 and B12 reduces homocysteine levels in patients with
Alzheimer disease (30).
9. Reducing the toxicity of chemotherapeutic agents.
Antimetabolites are active chemotherapeutic agents for many solid tumor
and hematologic malignancies. Folate antagonists, purine analogues, and
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pyrimidine analogues are the three main categories of antimetabolites.
Methotrexate is the most widely studied folate antagonist, and is effective in many
malignancies. Methotrexate resistance, which develops through several
mechanisms, may lead to cell death. Antifolate drug development has focused on
agents designed to overcome different aspects of methotrexate resistance.
Supplementation with folic acid and vitamin B12 has been shown to reduce
the toxicity of the antifolate agent, pemetrexed, and increase its therapeutic index
without affecting the efficacy of this novel agent (31).
Folic acid is gaining more clinical importance as a preventative agent for
many diseases. Extensive clinical research is underway to elucidate its mechanism
of action in preventing a disease, or to establish other potential clinical uses. Folic
acid is likely going to play a critical and major role in the prevention therapy of
many diseases in the future.
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Chapter II
Dissolution of Nutritional Supplements
Nutritional supplements such as vitamins, minerals, and botanicals (i.e.
nutraceuticals) are now becoming increasingly popular in the West, although the
Chinese have been using various nutritional supplements and herbs to cure many
body and soul maladies for centuries (32).
Nutraceuticals, especially folic acid, have received considerable attention in
the 1990s because of increasing clinical importance. Until the early 1990’s, there
were no guidelines or USP monographs that ensured the pharmaceutical quality of
marketed nutraceutical products. In 1938, the FDA, through Food Drug and
Cosmetic Act, categorized vitamins as food; thus, while vitamins need to be safe,
they have not undergone the same quality requirements and review scrutiny as
drug products, which are required to be safe and effective. However, during the
past decade, through a rigorous process of proposal review and guideline
selection, the United States Pharmacopoeia (USP) established its first protocols for
testing the vitamin and mineral contents of nutritional supplements (33, 34).
Additionally, the FDA focused serious attention on product claims and labeling
practices.
A primary concern is the pharmaceutical quality, potency, and efficacy of
nutritional supplements and their label claims. Under the 1994 Dietary
Supplement Health and Education Act (DSHEA), the FDA-required premarket
review of nutritional supplements is less in-depth than that of other products the
agency regulates, such as drugs and food additives. Thus, nutraceuticals continue
to be brought to market under less rigorous testing standards than are
pharmaceuticals. This means that consumers and manufacturers are responsible for
checking the safety, efficacy and truthfulness of label claims. DSHEA also
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allowed manufacturers to make therapeutic claims for the first time legally,
provided a “claim unfounded by the FDA” disclaimer was included.
USP monographs provide methods for evaluating the acceptability and
stability of pharmaceuticals in approved applications. Since the FDA was not
charged with regulating nutraceuticals as drugs in the early 1990s, USP addressed
this matter of public health through a process that led to the development of
monograph standards for many vitamins, mineral supplements and botanicals.

Table 1. Development of Nutritional Supplements Monographs in USP.

1991

USP holds an open conference on vitamins, minerals, and
nutritional supplements. The first proposals are discussed and
reviewed.

1993

Supplement 8 to USP XXII: The first standards are established,
including requirements for initial disintegration testing and for
dissolution testing if disintegration attempts fail. USP
Pharmacopeial Forum publishes a proposal for establishing
dissolution requirements for nutritional supplements.

1994

US Congress passes DSHEA.

1995

Supplement 1 to USP 23: Dissolution testing is established as a
requirement for nutritional supplements, including folic acid,
index vitamins, and index elements.

1995-1998

Subsequent USP 23 supplements: fine-tuning of requirements,
test methods, and assays.

1998

Inclusion of botanicals in USP/NF monographs.
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Standards for vitamins, including disintegration and dissolution test
requirements, first appeared in 1993 in the eighth supplement to USP 22/NF 17
(33). The USP section describes monograph test methods for vitamins and calcium
supplements. Testing is based on the product's end use and strength. For example,
if a calcium product is a compendial article and will be used as an antacid, the test
is a disintegration test. However, if the article will be used as a calcium
supplement for the treatment of osteoporosis, the test is a dissolution method.
Because manufacturers have no control over a product's end use, it becomes their
responsibility to see that a tested product would pass both disintegration and
dissolution tests throughout its shelf life. Additionally, if the product is labeled
"USP," it must be packaged, stored, and distributed as required in the monographs
and in conformance with USP General Chapters. It should be noted that
nutraceutical manufacturers are not required to meet USP monograph standards in
order to market their products. However, use of a USP label claim on the product
does require this, and failure to pass these standards would then be considered as
“product mislabeling or misbranding”, a punishable violation of FDA guidelines.
When establishing the test requirements for vitamins, USP considered the
degree of difficulty of the test and the number of active ingredients in the
formulation. For multivitamins, a list of index vitamins and minerals were chosen
based on their solubility. It was presumed that if the least-soluble active ingredient
in the formulation was dissolved, then the other actives in the product were also in
solution. Furthermore, USP provides for a less work intensive test by combining
aliquots from six tests for a single determination. These unique guidelines were
developed in order to keep the cost of testing multivitamins manageable. Table 2
lists the dissolution test requirements for the six USP classes of vitamins, minerals,
and vitamins with minerals.
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Table 2. USP Classifications with respective dissolution test requirements.

Class

Dissolution

I. Oil-soluble vitamins

Not required

II. Water-soluble vitamins

One index vitamin; folic acid if present

III. Water-soluble vitamins with

One index vitamin and one index

minerals

element; folic acid if present
One index water-soluble vitamin; folic

IV. Oil- and water-soluble vitamins

acid if present

V. Oil- and water-soluble vitamins with

One index water-soluble vitamin and

minerals

one index element; folic acid if present

VI. Minerals

One index element

In general, the dissolution conditions for index vitamins and index
minerals are
* Medium: 0.1 N hydrochloric acid, 900 mL
* Apparatus 1: 100 rpm for capsules
* Apparatus 2: 75 rpm for tablets
* Time: 1 hr.
For formulations containing >25 mg of the index vitamin riboflavin, the
dissolution medium should be 1800 ml of 0.1N hydrochloric acid, while for folic
acid, the dissolution medium should be 900 ml of distilled water. Folic acid is the
first index vitamin in the selection of an index. It is notable that folic acid
performance was considered critical enough by the USP that it is tested
independent of the index vitamin system.
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The USP dissolution requirements are met if at least 75% of the labeled
content of folic acid and at least 75% of the assayed content of the index vitamin
or index element from the units tested are dissolved in 1 hour.
The USP monographs also contained other tests to ensure the
pharmaceutical quality of nutritional supplements; this includes disintegration and
uniformity of the dosage. Disintegration is designed to determine dosage unit
compliance with disintegration specifications set in the nutritional supplements’
individual monographs. Failure of the product to disintegrate completely within
thirty minutes may be indicative of an ultimate poor and variable dissolution and
bioavailability of the product. Content uniformity test indicates the uniformity of
the distribution of the active over the number of the dosage units in the same
batch. To meet the requirement of this test, the percentage of the active ingredient
relative to the label claim in the dosage unit should be within the specified
percentage range in the individual monographs. This test indicates the truthfulness
of the label claim, and allows one to conclude whether the dosage unit passed the
dissolution specifications.
Standards for nutritional supplements were first proposed in Pharmacopeial
Forum in 1993 and accepted in 1995. The standards are provided in the Official
Monographs and General Chapters-General Test and Assays sections of USP
25/NF20 (35). These include chapters <2021> Microbial Limit Tests, <2040>
Dissolution of Nutritional Supplements, <2091> Weight Variation, and <2750>
Manufacturing Practices for Nutritional Supplements. These standard are similar
to those published as cGMP’s (Good Manufacturing Practices) for
pharmaceuticals in 21CFR 211. The standards in USP 25/NF 20 apply only to
articles that are labeled "USP". If tested, these materials must comply with USP
monograph standards, including those for dissolution and potency.
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Currently, there is an increased concern about folic acid and its importance
in the treatment and prevention of disease and in the decreased risk of neural tube
defects during fetal development. Additionally, patients are often titrated on
medications based on their regular dietary intake of folic acid-containing products
(5). Folic acid is a food additive in bread products and an ingredient in both
multiple and prenatal vitamins. These vitamin preparations may be either nonprescription (OTC) and prescription products. A prescription product status does
not imply that the product has been assessed as a drug, only that ingredient
amounts are in higher doses. It is critical to disease treatment that the folic acid
content of these products be as claimed on the label.
The increasing clinical importance of folic acid and the appearance of the
nutritional supplement chapter in USP raised the concern about the pharmaceutical
quality of commercially available folic acid products, whether single entity or in
multivitamins preparations, and their compliance to USP specification. Many of
those products were on the market before the appearance of the nutritional
supplements chapter in USP.
Our laboratory was the pioneer dealing with those concerns. Stout, et al
tested two vitamin classes, renal multivitamins and prenatal vitamins, using USP
standard disintegration methodology, as well as simulated gastric and intestinal
fluids. Product failure was determined based on USP guidelines. Of renal
multivitamins tested, 50% failed/ 38% passed disintegration standards under all
conditions. For prenatal vitamins, 54% failed / 31% passed under all conditions.
The results suggested potential poor bioavailability of less soluble product
components due to high variability in disintegration time; it also suggested the
need for further analytical studies (36). Dissolution studies performed in the three
worst performing (disintegration) products by an independent laboratory
confirmed that these products failed dissolution.
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In the late 1990’s, other laboratories showed that a majority of prenatal
products tested did not meet the minimal USP standards. Only three out of nine
multivitamin products met USP specifications for folic acid release, and most of
the products missed the minimum standard by a wide margin, with two products
releasing less than 25% of the labeled quantity (8).
Al-Achi and York compared three formulations of folic acid capsules on
the basis of weight variation, dissolution, disintegration and content uniformity.
The results of these pharmaceutical tests suggested that brands of folic acid
capsules might not be necessarily equivalent. Currently, there is no USP
monograph for folic acid capsules. Pharmacists recommending this dosage form
must exercise caution since some brands may not deliver the minimum
recommended daily dose of folic acid (37).
Six prenatal vitamin supplement products and one Prenate Advance®
product were tested for folic acid release (38). Of the seven products tested,
Prenate Advance® and another two of the vitamin supplement products met the
USP standard for folic acid release. Dissolution ranged from 78% to 110% of the
labeled folic acid content. With dissolution levels ranging from 0% to 38% of the
labeled claim, the remaining four products failed to achieve the USP standard. The
findings for multiple lots were consistent. Dissolution levels in one of the failing
products lots never rose above 10% and one lot yielded a dissolution result of zero
on initial testing.
Scuhrope, et al tested eleven brands of folic acid tablets (400 mcg),
available commercially in the United Kingdom, for compliance with the British
Pharmacopoeia (BP) test for dissolution. The requirement of this test is that, for
tablets and capsules, the amount of active ingredient released in distilled water in
one hour should not be less than 70 percent of the labeled amount. Six of the
eleven formulations tested passed the BP test for dissolution, while four of the
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brands failed to release 70 per cent of the labeled active drug in the first hour of
the test. One of the formulations failed to disintegrate and release the active
ingredient. Two of the brands that passed the test released more than 150 per cent
of the nominal 400 ug drug content, which highlights the problem of dose
uniformity (39).
As noted above, failure to meet USP specifications, which ensure the
pharmaceutical quality of folic acid products, is observed in high percentages
among tested products. Failure to meet the disintegration and dissolution
requirements may lead to a reduced bioavailability of the drug, which will
eventually reduce its therapeutic or preventative effect. Folic acid is absorbed in
the proximal part of the small intestine. Thus, if the folic acid dosage unit fails to
disintegrate and dissolve in the stomach, this will make folic acid less available for
absorption. The drug will pass through its absorption window in the upper
intestine without being completely absorbed, which will reduce its bioavailability.
Finally some manufacturers include more folic acid than the labeled
amount per dosage unit in order to bypass dissolution failure. However, this
practice might lead to elevated blood levels of folic acid that will initiate side
effects or toxicity. It is known that large amounts of folic acid alter the function of
anti-epileptic drugs. Moreover, consuming a high amount of folic acid can
eliminate the anemia and its symptoms, leaving individuals and their doctors
without the most obvious sign of too little vitamin B-12. But an individual can
continue to suffer from less noticeable neurological deterioration related to the B12 levels. Thus, high levels of folic acid can mask vitamin B-12 deficiency.
The global objective of this research is to assess the pharmaceutical
performance and quality of currently marketed folic acid nutraceuticals, compare
this with that of previous products, and identify those factors which contribute to
product failure. Specific goals include the following:
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1) By following USP monograph standards for disintegration, dissolution, and
content uniformity, the currently marketed commercial products will be assessed
for complying with USP monograph standards.
2) With an interest in product performance under physiological conditions,
disintegration and dissolution will also be performed in physiologically relevant
fluids (simulated gastric fluid, pH 1, and simulated intestinal fluid, pH 7.5). These
studies have implications for both in vivo performance, as well as future USP
standard test methodologies.
3) These results (items 1 and 2 above) will be compared with the results of
previous studies in this laboratory as well as in others to determine whether the
pharmaceutical quality of folic acid nutraceuticals has improved since the mid1990's, since this has implications for public health.
4) Assessment will be made as to whether one type of formulation (tablet vs
capsule, multivitamin vs single entity), in general, exhibits better performance
than the others.
5) One or more HPLC assays will be developed and validated in the laboratory for
use in assaying folic acid and its products of degradation. These assays will
include those recommended in USP monograph standards for folic acid/folic acidcontaining products. Historically, HPLC assays for folic acid have been
challenging to adopt from other laboratories and run reproducibly.
6) Subsequent to completion of all testing of commercial products, a failures mode
analysis will be performed to identify those factors that exhibit an influence on
folic acid performance (ie: pH, excipients, hardness). This will be useful in
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gaining a mechanistic understanding of product failure. Previously published
studies of folic acid products have not performed this analysis.
7) Previously published studies have also not performed studies of independent
variables that may contribute to product failure. To this point, the pH-solubility
profile of folic acid, as well as its stability, will be characterized. Laboratory
formulated folic acid tablets will also be manufactured in order to observe the
influence of both excipients and manufacturing conditions. Constant surface area
dissolution studies using laboratory formulated buffered and non-buffered folic
acid tablets will be conducted, to elucidate the effect of folic acid saturation
solubility on the dissolution profile and its contribution to product failure.
8) The results of the fundamental, mechanistic studies (items 6 and 7 above) will
be used to recommend formulation/ manufacturing conditions that may lead to
product optimization and improved pharmaceutical performance.
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Chapter III
Materials and Methods
Consistent with the goals of this research, two types of studies were
performed:
1) Those necessary to characterize the pharmaceutical quality of
commercially available folic acid products
2) Studies needed to evaluate and identify the potential causes of folic
acid product failure (i.e. mechanistic studies).
In order to test the pharmaceutical quality of commercially available folic
acid products, the following tests were performed:
I. Disintegration
II. Dissolution.
III. Content uniformity.
Studies done to independently assess folic acid characteristics, so as to
identify product failure causes and optimize product formulation, included:
I. Solubility.
II. Stability.
III. Laboratory formulated tablet dissolution.
IV. Buffered tablets constant surface area dissolution.
Materials
Below is a list of the chemicals, folic acid products and reagents prepared
to carry out the tests mentioned above.
A. Chemicals:
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Hydrochloric acid 12.1 N (Fisher), HPLC grade o-phosphoric acid 85%
(Fisher), 25% ammonium hydroxide solution in water (Fluka), sodium hydroxide
(Fisher), potassium monobasic phosphate (Fisher), sodium chloride (Fisher),
methyl-4-hydroxybenzoate (Fisher), HPLC grade potassium monobasic phosphate
(Fluka), N-(4-aminobenzoyl-L-glutamic acid) (Fluka), HPLC grade sodium
perchlorate (Fisher), 4-aminobenzoic acid (Fluka), folic acid (Sigma),
diethylenetriaminepentaacetic acid (pentitic acid) (Acros Organics), HPLC grade
tetrabutylammonium hydroxide 1 Molar in water (Fisher), methyl cellulose
(CCC), microcrystalline cellulose (Penwest Pharmaceutical Co.), croscarmellose
( Mylan Pharmaceutical), sodium citrate (Fisher), citric acid (Fisher), and calcium
stearate (Fisher), and stearic acid (Fisher)
B. Commercial nutraceuticals:
Single entity folic acid tablets: Folic Acid 400 mcg (Rite Aid), Folic Acid
400 mcg (Kroger), Folic Acid 400 mcg (PharmAssure), Folic Acid 400 mcg
(Nature Made), Folic Acid 400 mcg (Nature’s Bounty), Folic Acid 400 mcg
(Naturally Preferred), and Folic Acid 400 mcg (GNC).
Multivitamin tablets containing folic acid: Prenatal Tablets 800 mcg
(Kroger), Prenatal Tablets 800 mcg (Rite Aid), Prenatal 800 mcg (Eckerd), Stuart
Natal 800 mcg (Integrity), Stuart Natal Plus 3 800 mcg (Integrity), Nephron FA
1 mg (Nephro-Tech, INC), and Nephro-Vite 800 mcg (R & D Laboratory, Inc).
Multivitamin capsules containing folic acid: Nephrocaps 1 mg (Fleming &
Company Fenton).
C. Reagents:
1 N Hydrochloric Acid
Exactly measured 8.3 ml of 12.1 N HCl was added to 50 ml distilled water
in 100 ml volumetric flask and the volume was adjusted with distilled water.
0.2 N Sodium Hydroxide
Sixteen grams of NaOH were placed in a 2-liter volumetric flask, distilled
water was added to volume and the solution was mixed.
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1 N Sodium Hydroxide
Four grams of NaOH were placed in a 100 ml volumetric flask and diluted
with distilled water to volume and the solution was mixed.
3 N Phosphoric acid
Exactly measured 16.82 ml of 85% HPLC grade o-phosphoric acid was
transferred to a 250 ml volumetric flask, distilled water was added to volume and
the solution was mixed.
6 N Ammonium Hydroxide
Exactly measured 111.1 ml of 25% ammonium hydroxide solution was
transferred to a 250 ml volumetric flask, distilled water was added to volume and
the solution was mixed.
10% Ammonium Hydroxide
Forty ml of 25% ammonium hydroxide solution was transferred to a 100 ml
volumetric flask, distilled water was added to volume and the solution was mixed.
0.5 M Tetrabutylammonium Hydroxide in Methanol
Twenty five ml of HPLC grade 1 M tetrabutylammonium hydroxide in
water solution was placed in a 50 ml low actinic volumetric flask, HPLC grade
methanol was added to volume and the solution was mixed.
Reagent 1
Tetrabutylammonium hydroxide in methanol solution (25%) was prepared
by transferring 96.4 ml of 1 M tetrabutylammonium hydroxide in water to a 100
ml low actinic volumetric flask. HPLC grade methanol was added to volume and
the solution was mixed.
Reagent 2
Five grams of pentetic acid was transferred to a 50 ml low actinic
volumetric flask and diluted to volume with 1 N sodium hydroxide solution.
Simulated Gastric Fluid
Simulated gastric fluid was prepared according to USP standards (40). Six
grams of sodium chloride were placed in a 3-liter round bottom flask, and 2500 ml
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of distilled water and 21 ml of 1 N HCl were added. The volume was adjusted and
the solution pH was adjusted to 1.5 with either 1 N HCl or 0.2 N NaOH. No
enzymes were added to the fluid.
Simulated Intestinal Fluid
Simulated intestinal fluid was prepared according to USP standards (40).
20.4 g of potassium monobasic phosphate were placed in a 3-liter round bottom
volumetric flask, and 570 ml of 0.2 NaOH were added. The volume was adjusted
with distilled water. The solution pH was adjusted to 7.5 with either 1 N HCl or
0.2 N NaOH. No enzymes were added to the fluid.
Methods
Testing of performance of commercially available folic acid products
I. Disintegration:
Disintegration was performed according to section 701 of the USP (41)
using the three basket disintegration apparatus (Vankel). The apparatus consists of
a basket-rack holding six open-end glass tubes. Each is 7.75 ± 0.25 cm long and
has an inside diameter and wall thickness of approximately 21.5 and 2 mm,
respectively. Attached by screws to the underside of the lower plate holding the
tubes are a 10 mesh stainless steel wire cloth. The basket rack is suspended
through an arm immersed in a one liter beaker containing an appropriate fluid at
37± 2°C. The basket rack is raised and lowered through a distance of 5 to 6 cm at
a rate of 28 to 32 cycles per minute. The volume of the fluid is such that, during
the operation, the basket rack is never less than 2.5 cm below the surface of the
fluid or above the bottom of the beaker. The three beakers are held within a water
bath to maintain constant temperature.
To perform the test, one tablet was placed in each of the six tubes of the
basket, and 900 ml of the disintegration medium was brought to 37± 2°C. All
products tested fell within USP’s size diameter requirement for use of the six tube
basket. In each beaker, the baskets were hung from the moving arm, centered over
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the beaker and the study begun. Disintegration was timed from the start of the
arm’s movement. At frequent time intervals, the apparatus was stopped, the basket
was lifted from the fluid, and the tablets were evaluated for disintegration.
According to USP (41), the disintegration medium should be 900 ml of
distilled water, and disintegration should be run for thirty minutes. Complete
disintegration is defined as that state in which any residue of the unit, except
fragments of insoluble coating or capsule shell, remaining on the screen of the test
apparatus is a soft mass having no palpably firm core. In order to meet USP
specifications, six tablets should first be tested. If 1 or 2 tablets failed to
disintegrate completely, the test should be repeated on an additional twelve tablets.
Not less than 16 out of 18 tablets tested should disintegrate completely.
Unlike USP specifications, the test was performed in three media:
simulated gastric fluid (SGF) (pH 1.5), simulated intestinal fluid (SIT) (pH 7.5)
and distilled water (DW) (pH 5-6). The disintegration times for eighteen randomly
selected tablets from each product were measured at the same time if a preliminary
study of disintegration time gave disintegration time greater than 5 minutes;
otherwise, six tablets were measured at a time. The test was not stopped at 30
minutes, but continued until every tablet had disintegrated completely or up to 8
hours, whichever occurred first. The same tests were applied for the multivitamin
capsule product containing folic acid. Times were noted for the disintegration time
of each tablet, and there times (n=18) averaged to determine the “average time for
disintegration and variability” for that specific product. These data were then used
to determine:
1. Whether the product passed the USP monograph standard for
disintegration.
2. Exhibited a significantly short or long disintegration time.
3. Exhibited disintegration sensitivity to pH conditions.
4. Showed broad variability in disintegration to pH conditions.
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II. Dissolution
1) Dissolution for single entity folic acid tablets
Dissolution was measured using USP apparatus II and the test conditions
specified for folic acid tablets in USP (41). USP apparatus II consists of a covered
glass vessel that contains the dissolution medium. The tablet is placed in the vessel
and the dissolution fluid is stirred at 50 rpm with a paddle that is positioned one
inch above the bottom of the dissolution vessel. The 500 ml dissolution media was
equilibrated to 37±1°C.
To meet the USP specifications, folic acid tablets should release more than
75% of label claim in distilled water in 45 minutes (42). Unlike the USP method,
which requires one end-point measurement, dissolution was followed for one hour
and 0.5 ml from the dissolution medium from each vessel of the dissolution
apparatus was withdrawn every 15 minutes and transferred to a common sampling
receptacle. This allowed for the generation of a more complete dissolution profile
for each product. The dissolution media was replaced with fresh media after the
withdrawal of each sample. Sample collection took less than two minutes. Pooled
samples were filtered through 0.2 µm Nylon Membrane filters (by Whatman) into
an amber vial and the vial was immediately capped. Samples were assayed using
the set forth HPLC assay method for single entity folic acid tablets. The assay was
therefore performed on a pooled sample and provided an average of the folic acid
release across the six dosage forms at every sampling point. For every product
tested, dissolution was performed in three different media: simulated gastric fluid
pH (1.5), simulated intestinal fluid (pH 7.5) and distilled water (pH 5-6). Each test
was repeated three times for a total of eighteen tablets, with three pooled samples
per sample point/time (n=3).
HPLC assay of folic acid in tablets containing only folic acid as active ingredient (42).
Mobile Phase: 35.1 g of sodium perchlorate and 1.4 g of HPLC grade potassium
monobasic phosphate were transferred to a 1-Liter volumetric flask, and 7.0 ml of
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1N potassium hydroxide and 40 ml of methanol were added .The mixture was
diluted with water to volume, mixed and filtered (0.45 um filter). The solution pH
was adjusted to 7.2 using either 1N potassium hydroxide or 3N phosphoric acid.
HPLC system: The chromatographic system used consisted of the following:
Pump: Waters 515 HPLC pump.
Sampler: Waters 712 WISP auto sampler.
Detector: Waters 2487 UV detector.
Integrator: Millennium 3.1 chromatography software.
Column: Beckman octyl C18 ODS/ column 4.6 mm x 25 cm.
Flow rate: 1.0 ml/min
Detection wavelength: 245-nm.
Folic Acid standard stock solution: Exactly 100 mg of folic acid standard (USP)
was placed in a 100 ml low actinic volumetric flask. Two ml of 10% ammonium
hydroxide were added to dissolve the folic acid and the volume was adjusted with
mobile phase.
Standard preparation: One ml of folic acid stock solution was diluted to 100 ml in
the mobile phase to make a diluted stock solution (10µg/ml).
Assay Preparation: Diluted stock solutions of 0.1 to 1.0 ml were diluted to 10 ml
in distilled water to prepare standards for injection. The concentration range of the
standards was 0.1 to 1.0 µg/ml.
Method Validation: The method was validated for linearity, accuracy and
reproducibility. Standard preparations were prepared and each sample was injected
three times on three different days, and the area under the folic acid peak was
integrated. Linearity of the calibration curve was calculated, and the relative
standard deviation of the repeated injections was calculated to reflect accuracy and
reproducibility.
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2) Dissolution for folic acid in multivitamin dosage unit.
Dissolution was measured using USP apparatus I for capsules and II for
tablets along with the test conditions specified for folic acid tablets in the USP
(disintegration and dissolution of nutritional supplements) (43). USP apparatus II
consists of a covered glass vessel containing 900 ml of dissolution fluid. The tablet
is placed free in the bottom of the vessel and the dissolution fluid is stirred at 75
rpm with a paddle that is positioned one inch above the bottom of the dissolution
vessel. USP apparatus I consists of a covered glass vessel containing 900 ml of
dissolution fluid. The vessel is partially immersed in a suitable water bath placed
in a heating jacket. The tablet is placed within the basket positioned one inch
above the bottom of the dissolution vessel and the vessel is held by a shaft that
rotates and stirs the dissolution medium at 100 rpm. The 900 ml dissolution media
was equilibrated to 37±1°C.
In order to meet USP standards, 75% of the label amount of folic acid must
be released out of the multivitamin unit in 60 minutes (43). Unlike the USP
method, which gives a single point measurement, dissolution was followed for one
hour and 0.5 ml from the dissolution medium from each vessel of the dissolution
apparatus was withdrawn every 15 minutes and transferred to a common sampling
receptacle. This allowed for the generation of a more complete dissolution profile.
The dissolution media was replaced with fresh media after the withdrawal of each
sample; sample collection took less than two minutes. Pooled samples were
filtered through 0.2 µm Nylon Membrane filters (by Whatman) into an amber vial
and the vial was immediately capped. Samples were assayed using the set forth
HPLC assay of folic acid as an ingredient of pharmacopeial preparations
containing other active constituents (44). The assay was therefore performed on a
pooled sample and provided an average of the folic acid release across the six
dosage forms. For each product tested, dissolution was performed in three
different media: simulated gastric fluid (pH1.5), simulated intestinal fluid (pH 7.5)
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and distilled water (pH 5-6). Each test was repeated three times for a total of
eighteen tablets, with three pooled samples per sampling point/ time ( n=3).
HPLC assay of folic acid as an ingredient of pharmacopeial preparations
containing other active constituents (44).
Mobile phase: 2.0 g of monobasic potassium phosphate were placed in 1-liter
volumetric flask, and dissolved in about 650 ml of distilled water. 12.0 ml of 25%
tetrabutylammonium hydroxide in methanol, 7.0 ml of 3 N phosphoric acid, and
240 ml of methanol were added. The solution was allowed to cool to room
temperature, then adjusted with either 3 N phosphoric acid or 6 N ammonium
hydroxide to a pH of 7 and mixed. The solution was then filtered using a 0.45 um
filter and the pH was rechecked before use.
HPLC system: The chromatographic system used consisted of the following:
Pump: Waters 515 HPLC pump.
Sampler: Waters 712 WISP auto sampler.
Detector: Waters 2487 UV detector.
Integrator: Millennium 3.1 chromatography software.
Column: Nova-Pak Waters C18 / column 3.5 mm x 15 cm.
Flow rate: 1.0 ml/min
Detection wavelength: 280-nm.
Diluting solvent: 200 mg of monobasic potassium phosphate was placed in a 100
ml low actinic volumetric flask and dissolved in approximately 60 ml of distilled
water. Then, 22 ml of methanol, 1.9 ml of reagent 1, 0.7 ml of 3 N phosphoric
acid, and 3 ml of reagent 2 were added to the mixture and the pH was adjusted to a
pH of 9.8. Nitrogen was bubbled through the solution for 30 minutes.
Internal standard solution: 25.0 mg of methylparaben was dissolved in 2.0 ml of
methanol, diluted with the diluting solvent described above to 50 ml and mixed.
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Standard folic acid solution: Accurately weighed 20 mg of folic acid standard
(USP) was placed in a 100 ml low actinic volumetric flask and dissolved in the
diluting solvent described above.
Standard Preparation: 2.0 ml of standard folic acid solution was transferred to a
low actinic, 50 ml volumetric flask. 2.0 ml of the internal standard solution was
added and the solution was adjusted to volume with the diluting solvent described
above and mixed.
Assay for injection: Standard preparation solutions of 0.5 to 5.0 ml were diluted
to 10 ml in distilled water to prepare standards for injection. The concentration
range of the standards was 0.2 to 2.0 µg/ml.
Method Validation: The method was validated for linearity, accuracy and
reproducibility. Standard preparations were prepared and each sample was injected
three times on three different days, and the area under the folic acid peak was
integrated. Linearity of the calibration curve was calculated, and the relative
standard deviation (i.e. coefficient of variation = (SD / average) X 100) of the
repeated injections was calculated to reflect accuracy and reproducibility.
III. Uniformity of dosage units.
The uniformity of dosage units can be demonstrated by either of two
methods, weight variation or content uniformity. A content uniformity test is
performed to ensure that the folic acid containing dosage unit does not have less or
more than the specified percent of folic acid relative to label claim.
1) Content uniformity determination of single entity folic acid tablets:
To meet USP requirements, folic acid tablets should contain not less than
90.0 percent and not more than 115.0 percent of the labeled folic acid amount
(42).
Twenty-five tablets of commercially available single entity folic acid
products equivalent to 10 mg of folic acid were finely powdered and transferred to
a 50 ml volumetric flask. A solvent containing 1 g of sodium perchlorate and 2 ml
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of 10% ammonium hydroxide dissolved in 100 ml distilled water was used to
dilute the powdered folic acid tablets. The mixture was shaken gently until folic
acid had dissolved and adjusted to volume with the same solvent. The mixture was
filtered by using a dry filter and discarding the first portion of the filtrate. A
portion of the clear filtrate was diluted quantitatively and stepwise with the same
solvent mentioned above to obtain a solution having approximated concentration
of 0.05 to 0.2 mg/ml. Folic acid standards for injection in the concentration range
of 0.05-0.2 mg/ml were prepared as described under the HPLC assay of folic acid
in single entity tablets (p.27). A folic acid calibration curve was first constructed,
then the assay preparations were analyzed. Both the standard preparations and the
assay preparation were injected in equal volumes in the HPLC system described
for the single entity folic acid tablets (p.27), and the response of the major peak
recorded. The area under the major peak was integrated. The procedure described
(i.e. injection of standard and assay preparations) above was repeated three times.
Average amount of folic acid per tablet was calculated by:
1. Determining sample concentration from calibration curve.
2. Adjusting for sample dilutions.
3. Divide by twenty five to obtain amount per tablet.
Content uniformity determination of folic acid in multivitamin dosage unit:
To meet the USP requirements for the uniformity of the dosage form, folic
acid containing multivitamin tablets should contain, on average, not less than
90.0% and not more than 150.0% of the labeled folic acid amount (43).
Internal standard preparation: Accurately weighed 40 mg of methylparaben was
transferred to a 1-liter volumetric flask, and 220 ml of methanol was added to
dissolve the methylparaben. In a separate beaker, 2.0 g of monobasic potassium
phosphate was dissolved in about 300 ml of distilled water. This solution was
quantitatively transferred to the flask containing the methylparaben solution, and
then an additional 300 ml of distilled water was added. 19 ml of Reagent 1, 7.0 ml
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of 3N phosphoric acid, and 30 ml of Reagent 2 were added. The solution pH was
adjusted to 9.8 using 6 N ammonium hydroxide. Nitrogen was bubbled though the
solution for 30 minutes and the solution was diluted with distilled water to volume
and mixed.
Assay Preparation: 30 tablets of commercially available multivitamin dosage unit
containing folic acid were weighed and finely powdered. Three portions of the
powder, equivalent to about 0.4 mg of folic acid, were weighed. Each portion was
placed in a 50 ml amber-colored centrifuge tube. 25.0 ml of internal standard
solution preparation were added, a stopper was added, and the mixture was shaken
for ten minutes and centrifuged for ten minutes at 4000 rpm. A portion of the clear
supernatant fluid was filtered and used for assay.
Standard preparation: Folic acid standard solutions in the concentration range 1040 µg/ml were prepared as indicated in the standard preparation under HPLC
assay of folic acid as an ingredient of pharmacopeial preparations (p.30).
Procedure: Folic acid standards were used to construct a calibration curve then the
assay preparations were analyzed. Folic acid standard and assay preparations were
injected separately in equal volumes in the chromatographic system described
under the HPLC assay of folic acid as an ingredient of pharmacopeial preparations
(p.30). The response of the major peak was recorded and the area under the peak
was integrated.
Average amount of folic acid per tablet was calculated by:
1. Determining sample concentration from calibration curve.
2. Adjusting for sample dilutions.
3. Divide by thirty to obtain amount per tablet.
Product failure analysis: Independent studies
I. Solubility
As an acid, folic acid is expected to have a higher solubility in basic pH
than in acidic pH. In order to determine the solubility of folic acid in different
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pHs, a solubility-pH profile of folic acid was generated by measuring the
solubility of folic acid at five different pH’s in buffers at pH 1,3,4,7 and 10
(Table 3) .
pH

Buffer Composition

1

25 ml of 0.2 M KCl + 67.0 ml of 0.2 M HCl.

3

50 ml of 0.1 M potassium hydrogen phthalate + 22.3 ml of 0.1 M HCl.

4

50 ml of 0.1 M potassium hydrogen phthalate + 0.1 ml of 0.1 M HCl.

7

50 ml of 0.1 M potassium monobasic phosphate + 29.1 ml of 0.1 M NaOH.

10

50 ml of 0.025 M borax + 18.3 ml of 0.1 M NaOH.

Table 3. Composition of the buffers.
Using a 50-ml volumetric flask, a saturated solution of folic acid was
prepared in a buffer at each pH, by adding an excess amount of folic acid. The
flasks were then placed in a water bath maintained at 37±1 °C with constant
shaking. Samples from each flask were withdrawn every day, diluted with mobile
phase and assayed using the set forth HPLC assay method for folic acid. The
measurement was stopped when the folic acid concentration was constant for three
consecutive days, indicative of the solution reaching a saturated state. The HPLC
chromatograms were checked for presence of degradation products every time
samples were assayed, by observing the presence of any representative peaks.
Saturation solubility was calculated by determining the samples concentration
from calibration curve and adjusting for sample dilutions.
HPLC assay of folic acid (45)
Mobile phase: 2.0 g of HPLC grade monobasic potassium phosphate were placed
in a 1-liter volumetric flask, and dissolved in about 650 ml of distilled water. 7.0
ml of 3N phosphoric acid, 15.0 ml of solution of 0.5 N tetrabutylammonium
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hydroxide in methanol, and 270 ml of methanol were added. The solution was
allowed to cool to room temperature, then adjusted with either 3N phosphoric acid
or 6N ammonium hydroxide to a pH of 5 and mixed. The solution was then
filtered using a 0.45 µm filter and pH was rechecked before use.
HPLC system: The chromatographic system used consisted of the following:
Pump: Waters 515 HPLC pump.
Sampler: Waters 712 WISP auto sampler.
Detector: Waters 2487 UV detector.
Integrator: Millennium 3.1 chromatography software.
Column: Agilent Hypersil C18 ODS/ column 4.0 mm x 25 cm.
Flow rate: 1.2 ml/min
Detection wavelength: 280 nm.
Internal standard solution: 50.0 mg of methylparaben was dissolved in a 1.0 ml of
methanol, diluted with the mobile phase to 50 ml and mixed.
Standard folic acid solution: Accurately weighted 100 mg of folic acid standard
(USP) was transferred to a 100 ml low actinic volumetric flask; 2 ml of 10%
ammonium hydroxide was added to dissolve the folic acid. The solution was
adjusted to volume with the mobile phase.
Standard Preparation: 2.0 ml of standard folic acid solution was transferred to a
low actinic 50 ml volumetric flask. 4.0 ml of the internal standard solution was
added and the solution was adjusted to volume with the mobile phase and mixed.
Standards for injection: Standard preparation solutions of 0.125 to 5.0 ml were
diluted to 10 ml in distilled water to prepare standards for injection. The
concentration range of the standards was 0.0005 to 0.2 mg/ml.
Method Validation: The method was validated for linearity, accuracy and
reproducibility. Standard preparations were prepared and each sample was injected
three times in three different days, and the area under the folic acid peak was
integrated. Linearity of the calibration curve was calculated, and the relative
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standard deviation (i.e. coefficient of variation = (SD / average) X 100) of the
repeated injections was calculated to reflect accuracy and reproducibility.
II. Degradation.
The folic acid HPLC assay (p34) was tested for its ability to detect paminobenzoyl-L-glutamic acid and p-aminobenzoic acid peaks. The two
degradation products were obtained from Fluka. In aqueous solution, paminobenzoyl-L-glutamic acid and pterine-6-carboxylic acid are the major
degradation products of folic acid, along with traces of p-aminobenzoic acid (47).
Stock solutions were prepared of each of them in the same manner
described for folic acid in page 34. Different dilutions of the two compounds in
the concentration range 1-25 ug/ml were prepared and assayed by the folic acid
HPLC assay. Mixtures of the two compounds with folic acid and methylparaben in
different proportions were also prepared and assayed using the folic acid HPLC
assay, in order to simulate the folic acid degradation process. The obtained
chromatograms were visually inspected for resolution and ability to pick up
degradation products in low proportions. Regression analysis of the area under the
peaks was performed to validate the ability of the method to quantitatively
measure those degradation products.
The HPLC assay for folic acid in single entity dosage units (p.27) was also
tested for its ability to detect folic acid degradation products. To perform this, folic
acid standard solution (1 mg/ml) was prepared in the same manner described for
folic acid on page 27. Then, this solution was diluted to 100 µg /ml with distilled
water, and assayed using the HPLC assay for folic acid in single entity dosage
units. The solution was then placed in a capped transparent glass container, and
maintained at room temperature to induce degradation of folic acid. Samples from
this solution were withdrawn and assayed every day until the folic acid peak
disappeared. The obtained chromatograms were visually inspected for resolution
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between the diminishing folic acid and the increasing folic acid degradation
products peaks.
III. Laboratory-prepared tablet formulations
To determine whether the formulation excipients have pronounced effect on
the dissolution of folic acid tablets in simulated gastric fluid, laboratory
formulated folic acid tablets (800 and 600 mcg) were prepared, starting with folic
acid and filler. Other excipients were then selected based either on their use in the
commercial products or their functional use. Exipients were then added to the
formulation, as listed in Table 4.
Ingredients

M
M1
M2
M3
M4
M5
A
A1
A2
A3
A4
A5
NBT
BT

MC + FA
MC + FA + Stearic Acid (1%)
MC + FA+ Stearic Acid (5%)
MC + FA+ Calcium Stearate (1%)
MC + FA +Calcium Stearate (5%)
MC + FA+ Calcium Stearate (1%)+
Croscarmellose (10%)
MCC+ FA
MCC+ FA + Stearic Acid (1%)
MCC + FA+ Stearic Acid (5%)
MCC + FA + Calcium Stearate (1%)
MCC + FA+ Calcium Stearate (5%)
MCC + FA+ Calcium Stearate (1%)+
Croscarmellose(10%)
MC + FA
MC + FA +25% citrate buffer (sodium
citrate and citric acid 2:1)

Tablet Weight
(mg)
400
400
400
400
400
400

FA (mcg)

300
300
300
300
300
300

600
600
600
600
600
600

400
400

800
800

800
800
800
800
800
800

MC: Methyl Cellulose.
FA: Folic Acid.
MCC: Microcrystalline Cellulose.
NBT: Non-Buffered Tablets.
BT: Buffered Tablets.

Table 4. Folic acid laboratory formulated tablets composition
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Folic acid tablets were manufactured in the following manner. First, 16 mg
of folic acid were accurately weighed. Then, the other inactive ingredients were
also accurately weighed according to their desired percentage in the total batch
weight. All the weighed powders were transferred to a V-shaped mixer and were
mixed manually (200 revolutions); this number of revolutions provides a
homogenous mixing for the formulation ingredients. The total weight of each
batch was eight grams.
An accurately weighed portion of the powder (0.3g or 0.4 g) was
transferred to a stainless steel die. The powder was then compressed for 10
seconds using a Carver laboratory press. The tablets were visually inspected to
confirm that they were free from flaws, such as lamination and capping. All
tablets were made twenty four hours prior to the dissolution run, and kept under a
clean inverted 25 ml beaker until the time of the run. Eighteen tablets were made
in each batch. All the produced tablets were weighed. Six tablets were tested for
hardness using a Vector / Schleuniqer hardness tester. The remaining tablets were
tested for dissolution in the same manner mentioned for single entity folic acid
tablets (p.27). The products’ dissolution profiles were compared to assess whether
an individual excipient (i.e. lubricant) or manufacturing condition (i.e. mixing
time) might contribute to the dissolution failure of folic acid tablets.
V. Self-Buffering tablets and constant surface area dissolution.
To determine whether the saturation solubility of folic acid as a function of
pH influences the dissolution of folic acid, a buffered tablet was formulated for
constant surface area dissolution. Two folic acid formulations were prepared. One
contained folic acid and methyl cellulose, and the other contained folic acid,
methyl cellulose and 25% citrate buffer sodium citrate and citric acid 2:1 (Table
4). In a separate experiment, the pH of this buffer was measured to be 4.5. Folic
acid tablets from each formulation were prepared the same way described above
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for laboratory tablet formulations. The tablet was then compressed into the die so
that the exposed surface of the tablet was flush with the die opening.
The die, holding the tablet, was then hung in a beaker containing simulated
gastric fluid kept at 37± 1°C by a water bath, with no stirring, and remained in the
die for the study. This configuration allows the dissolution to be measured from a
constant surface area, eliminating particulate surface area changes. It allows for a
more sensitive measure of the effect of concentration gradient and solubility upon
dissolution kinetics. Samples were withdrawn frequently directly from the area
below the surface of tablet and assayed by HPLC assay for single entity folic acid
tablets (p.27). Samples were withdrawn at 0, 15, 30, 45, 60, 75, 90, 120, 180, 240,
and 300 minutes, and a dissolution profile generated. The profiles for the non and
self-buffered tablets were compared to assess the influence of surface pH on folic
acid release kinetics.
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Chapter IV
Results and Discussion
I. Assay Development
Quantitative analysis of folic acid is usually associated with analytical
problems. The compound is easily oxidized and is decomposed in the presence of
light, high temperature and metal ions (46). HPLC analysis with UV detection is
the most effective method for folic acid quantification, since folic acid fluoresces
after activation by ultraviolet radiation (47). However, nine different HPLC assay
methods have been reported for folic acid HPLC assay (48).
Folic acid HPLC analysis is not a straight forward procedure that can be
performed easily. Sensitivity and high background noise are analytical problems in
the folic acid assay. The glassware used should be low actinic, so as to reduce the
degradation of folic acid catalyzed by light. The low solubility of folic acid in
water makes stock solutions difficult to prepare. Alkalinization of folic acid
solutions (usually with 10% NH3) enhances solubilization.
Modification of the reported methods is a strategy to improve the quality of
the assay. Modifications might be sometimes mandatory depending on the
instrument used and operating conditions. Validation of the method is required,
along with generation of a calibration curve with each assay of unknown samples.
The HPLC methods used were validated for linearity, precision and
reproducibility. The linearity of the method is a measure of how well a calibration
plot response against concentration approximates a straight line. Reproducibility
ensures that same response will be produced for a certain concentration each time
the assay is performed. Precision is indicated by low variation upon repeated
injections.
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1. HPLC assay of folic acid
The dependence of detector response on the amount of the injected folic
acid was examined to determine which of the elaborated conditions for HPLC
folic acid assay described in chapter III are most favorable for the assay of folic
acid. This dependence was examined in the concentration range 0.5 µg/ml to 200
µg/ml, which covers the solubility range of folic acid at different pH values. Folic
acid solutions were prepared at the following concentrations: 0.5 µg/ml, 1.0 µg/ml,
6.25 µg/ml, 12.5 µg/ml, 25.0 µg/ml, 37.5 µg/ml, 50 µg/ml, 75 µg/ml, 100 µg/ml,
150 µg/ml and 200µg/ml. Each solution was injected on the column three times.
The described solutions were freshly prepared three times at three different days
and the area under the peak of folic acid was integrated. The linear dependence of
detector response on the folic acid concentration was obtained. The regression
coefficient was 0.999 (Figure 3). The method accuracy and reproducibility in the
linear range was also determined on the basis of the relative standard deviation.
For all the tested solutions, the coefficient of variation was less than 3% upon
repeated injections (Table 5). Retention time was 12.0 minutes for folic acid and
24 minutes for methylparaben.
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Figure 3.The linearity of folic acid HPLC assay.

Folic Acid
(µg/ml)
0.5
1.0
6.25
12.5
25
50
100
200

CV
2.26
1.18
0.94
1.74
2.23
0.37
2.08
1.97

Table 5. Coefficients of variation of HPLC folic acid assay.
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250

2. HPLC assay for single entity folic acid tablets.
Individual standard solutions of folic acid in the concentrations 0.1 µg/ml,
0.2 µg/ml, 0.4 µg/ml, 0.8 µg/ml, and 1.6 µg/ml were prepared. This is the
concentration range where single entity folic acid tablet dissolution data are
expected to occur. In each set of the standard solutions, a linear relationship
between the area under the peak and concentration was observed in the specified
range. Regression analysis of the data (n=3) are reported in Figure 4. The results
showed good accuracy and reproducibility, as revealed by the coefficient of
variation (Table 6). The retention time for folic acid was 10.0 minutes ( no internal
standard was used for this assay).

Folic Acid
(µg/ml)
0.1
0.2
0.4
0.6
0.8
1
1.6

CV
2.18
1.21
2.41
0.25
1.38
2.77
0.97

Table 6. Coefficients of variation of single entity folic acid tablets HPLC assay.
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Figure 4. The linearity of single entity folic acid HPLC assay.
Ability of the assay methods to detect degradation products.
Folic acid is sensitive to heat, light and pH. It degrades by hydrolysis and
photolysis. In aqueous solution, p-aminobenzoyl-L-glutamic acid and pterine-6carboxylic (Figure 5) acid are the major degradation products of folic acid, along
with traces of p-aminobenzoic acid (47).
N
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N
N

O
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H2N

C OH
O

H

HN

C

O

C

C

CH2

C

O

O

O

Pterine-6-carboxylic acid

p-aminobenzoyl-L-glutamic acid

Figure 5. Pterine-6-carboxylic acid and p-aminobenzoyl-L-glutamic acid structures.
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Degradation of the active ingredient, whether it is during the formulation
process or in the final dosage unit, might be the reason behind failure of the
dosage unit to meet the dissolution requirement; i.e. the amount of active
ingredient available for dissolution is less than the label claim due to loss of the
active by degradation. To address that, the HPLC methods being used were
assessed for their ability to detect at least one of the degradation products, so as to
determine qualitatively and quantitatively if major loss of the active ingredient had
occurred.
The folic acid HPLC assay was evaluated for its ability to detect paminobenzoyl-L-glutamic acid and p-aminobenzoic acid. The two degradation
products were obtained from Fluka. Stock solutions were prepared of each of them
in the same manner described for folic acid (p 34). Dilutions of the two
compounds in the concentration range of 1-25 µg/ml were prepared and assayed
by folic acid HPLC assay.
Regression analysis of the data (n=3) indicated the validity of the method
to detect the presence of the two degradation products, with r2 values obtained
>0.99 and RSD < 5 % upon replicate sample analysis. A mixture of the two
degradation products with folic acid was prepared in different proportions and
measured. The results showed a good resolution and separation between the peaks.
Peaks corresponding to traces of p-aminobenzoic acid and p-aminobenzoyl-Lglutamic acid (~ 3.0% of the total solution) were detected. Retention times were
3.7, 6.0 and 12.0 minutes for p-aminobenzoic acid, p-aminobenzoyl-L-glutamic
acid, and folic acid, respectively (Figure 6). These results demonstrated the
sensitivity of the assay for folic acid to the presence of degradation products in
pure drug samples (for example, saturation solubility studies) and the assay’s
ability to quantitate these products.
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Figure 6. Chromatogram of mixture of p-aminobenzoic acid (5 µg/ml) p-aminobenzoylL-glutamic acid (5 µg/ml) and folic acid (5 µg/ml).
The HPLC assay for folic acid in single entity dosage units was also tested
for its ability to detect folic acid degradation products. To perform this, folic acid
standard solution (1 mg/ml) was prepared in the same manner described on page
27. Then, this solution was diluted to 100 µg/ml with distilled water, and assayed
using the HPLC assay for folic acid in single entity dosage units. The solution was
then placed in a capped transparent glass container, and kept at room temperature
to induce degradation of folic acid. Samples from this solution were withdrawn
and assayed every day until the folic acid peak (RT 10.3 minutes) was reduced by
> 90 % Two peaks other than the folic acid peak were obtained, corresponding to
p-aminobenzoyl-L-glutamic acid (RT 2.8 minutes) and pterine-6-carboxylic acid
(RT 5.5 minutes), respectively (Figure 7). Since pterine-6-carboxylic acid was not
available commercially, no calibration curves were generated for this degradation
product in this study. However, the study did demonstrate a sensitivity of the
HPLC assay method for single entity dosage units to the presence of these two
degradation products.
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A.

B.

Figure 7. Chromatogram of folic acid degradation (100 ug/ml); A. Day 1, B. Day
15.
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3. HPLC assay of folic acid in multivitamin dosage units.
The response of the area under the peak against the amount of the injected
folic acid was examined to determine if the described assay conditions may be
applied for the assay of folic acid in multivitamin tablets. This response was
examined in the concentration range of 0.2 µg/ml to 2.0 µg/ml, which covers the
dissolution range of folic acid in the tested multivitamin preparations. To execute
this, folic acid solutions were prepared at the following concentrations: 0.2 µg/ml,
0.4 µg/ml, 0.6 µg/ml, 0.8 µg/ml, 1.0 µg/ml, 1.2 µg/ml, 1.4 µg/ml, 1.6 µg/ml, 1.8
µg/ml and 2.0 µg/ml. Each solution was injected on the column three times. The
described solutions were prepared fresh three times at three different days and the
area under the peak of folic acid was integrated.
The linear dependence of area under the peak on the folic acid
concentration, in the examined range of concentration, was obtained. The
regression coefficient was 0.99 (Figure 8). The method accuracy and
reproducibility in the linear range was also determined on the basis of the relative
standard deviation. For all the tested solutions, the coefficient of variation was less
than 3% upon repeated injections (Table 7). The retention time was 3.1 minutes
for folic acid and 15 minutes for methylparaben. The assay did not show
sensitivity for folic acid degradation products. The short retention time for folic
acid makes it difficult to resolve folic acid peak from its degradation products
peaks when a mixture of folic acid and p-aminobenzoyl-L-glutamic acid was
assayed.
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Folic Acid
(µg/ml)
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0

CV
1.67
1.25
2.19
0.32
2.18
1.95
1.49
1.56
1.21
1.44

Table 7. Coefficient of variation of folic acid HPLC assay in multivitamin dosage units.

1e+6

Area Under the Peak

8e+5

6e+5
R2=0.987
Y =3.9e+5 X +5.9e+4
R2=0.986

4e+5

Y =3.9e+5 X +6.4e+4
R2=0.990

2e+5

Y =3.9e+5 X +5.4e+4
Regression Line

0
0.0

0.5

1.0

1.5

2.0

2.5

Folic Acid (ug/ml)

Figure 8. The linearity of folic acid HPLC assay in multivitamin dosage units.
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II. Product Performance-Commercial
Disintegration
The disintegration test is provided to determine compliance with the limits
on disintegration stated in the individual USP monographs, except where the label
states that the tablets or capsules are intended for use as troches, or are to be
chewed, or are designed as a modified-release dosage form.
A tablet is generally formulated with a disintegrating agent which will
cause the tablet to rupture and fall apart in water or gastric fluid. Factors affecting
the disintegration of tablets include:
1. Physical and chemical properties of the granulation.
2. Tablet hardness.
3. Tablet porosity.
4. Disintegrating agent used.
Disintegration does not imply complete solution of the unit or even of its
active constituents. Complete disintegration is defined as that state in which any
tablet residue remaining on the screen of the disintegrating apparatus is a soft mass
having no palpably firm core.
To meet the USP requirement, the dosage unit should disintegrate, in the
specified disintegration medium in the individual USP monograph for that dosage
unit, in less than thirty minutes. This time has some in vivo relevance in that,
dosage units with excessively long disintegration times (>> 30 minutes) will likely
have minimal area available to dissolute, minimizing product bioavailability.
Tables 6 and 7 and Figures 9 and 10 show the average disintegration time
(n=3) for the tested products. Unlike the USP requirements for the disintegration
medium to be distilled water (DW), the test was also performed in simulated
gastric fluid (SGF) and simulated intestinal fluid (SIF) to characterize the product
disintegration at different pH values. Thirteen out of the fourteen products passed
the USP requirement for disintegration (less than 30 minutes).Few products
exhibited increased or decreased disintegration time trend with increasing pH. In
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general, disintegration was faster in acidic conditions and slower in neutral
conditions. Disintegration showed sensitivity to pH which reflects the influence of
varying excipients of the various formulations (Figures 11, 12).
Product

Mean Disintegration Time ± SD (min)

Pass/Fail

1

DW
138 ±138.5

SGF
18.0 ± 11.9

SIF
267 ± 207.6

Fail

2

0.4 ± 0.04

0.43 ± 0.07

0.53 ± 0.1

Pass

3

8.0 ± 0.31

9.7 ± 0.5

8.6 ± 0.2

Pass

4

0.7 ± 0.1

1.05 ± 0.1

1.28 ± 0.1

Pass

5

0.25± 0.03

0.185±0.02

0.19 ± 0.02

Pass

6

7.3 ± 0.5

8.4 ± 0.4

8.8 ± 0.3

Pass

7

10.5 ± 0.4

12.92 ±0.9

8.83 ± 0.8

Pass

Table 8. Single entity folic acid tablets average disintegration time in minutes.
Product

Mean Disintegration Time ± SD (min)

PMV1*

DW
8.12 ± 1.3

SGF
8.7 ± 1.2

SIF
10.5 ± 0.9

Pass

PMV 2*

10.0 ± 1.8

8.5 ± 1.3

9.5 ± 1.7

Pass

PMV 3*

8.4± 0.5

8.5 ± 0.4

10.9 ± 0.9

Pass

PMV 4*

19.3 ± 0.6

18.8 ± 2.0

22.3 ± 0.9

Pass

PMV 5*

11.0 ± 0.5

10.1 ± 0.7

10.7 ± 0.7

Pass

NMV1**

4.3 ± 0.7

4.4 ± 0.8

3.8 ± 0.7

Pass

NMV2**

14.5 ± 1.4

14.5 ± 1.3

15.5 ± 1.3

Pass

NMV3**

25.5 ± 1.6

22.2 ± 1.6

24.2 ± 3.4

Pass

Pass/Fail

* Prenatal multivitamin Tablet. ** Nephritic Multivitamin dosage Unit.

Table 9. Multivitamin dosage units containing folic acid average disintegration
time in minutes.
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Figure 9. Single Entity folic acid tablets average disintegration.
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Figure 10 . Multivitamin dosage units containing folic acid average disintegration.
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Figure 11. Single entity folic acid tablets average disintegration as a function of
pH.
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Figure 12. Multivitamin dosage units containing folic acid average disintegration
as a function of pH..
53

Of the fifteen products tested, only one, a single entity folic acid tablet

formulation #1, failed to pass the USP requirements and exhibited unpredicted
disintegration behavior (11->480 minutes). The reason for this might be in the
formulation as the label claims the absence of starch, yeast and preservative in the
product. The first two could contribute to the disintegration process. This might
also be attributed to the characteristics of the excipients at different pH values.
Hardness may also be a factor, as the measured hardness (9.81± 0.87 Kp) is
somewhat high for immediate release tablets; the small variability in hardness,
however, did not explain the wide variability in disintegration time. The second
slowest disintegrating product (NMV3) did not demonstrate as a wide range in
disintegration time (20.8-27.8 minutes).
. All the tablets disintegrated in less than thirty minutes in SGF.This was
not the case in DW. Since the tablet spends about two hours in the stomach before
being transported to the small intestine, the question as to whether the
disintegration test for folic acid containing dosage units should be carried out in
DW, as currently required by USP, or SGF, which is more physiologically
relevant, needs to be considered.
Content Uniformity
This test is designed to provide compliance of the dosage units with USP
specifications for the uniformity of the dosage unit. The uniformity of the dosage
unit can be demonstrated by either one of two methods, weight variation or
content uniformity.
Content uniformity of single entity folic acid tablets.
To meet the USP requirements for the uniformity of the dosage form,
single entity folic acid tablets should contain on average not less than 90.0% and
not more than 115.0% of the label claim and the relative standard deviation should
be less than 6 %. The average percent per tablet (n=25) and the relative standard
deviation were calculated as follows:
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Percent average = (Average amount per tablet/Label claim)* 100
Relative standard deviation = (100 * Average amount per tablet)/ Standard deviation
Table 10 contains the percent amount of folic acid per tablet (all tablets
labeled as containing 400 mcg) and the relative standard deviation for the tested
products. Six out of the seven products passed the USP requirement for the content
uniformity of single entity folic acid products. One of the tested products (#2)
contained 141% (564 mcg) of the labeled amount; this is considered a failure in
the dosage form and has a significant clinical importance since pharmacological
doses of folic acid may interfere with the efficiency of certain anticonvulsants
and/or mask vitamin B deficiencies. Samples analysis did not show any major
degradation in the formulations tested.
Product
1
2
3
4
5
6
7

Average Percent
Per Tablet
105.5%
141.0%
102.8%
102.5%
102.3%
101.3%
101.5%

RSD

Pass/ Fail

3.6
5.1
5.3
2.7
2.1
5.9
1.9

Pass
Fail
Pass
Pass
Pass
Pass
Pass

Table 10. Average percent of folic acid in single entity folic acid tablets.
Content uniformity of folic acid in multivitamin preparations:
To meet the USP requirements for the uniformity of the dosage form, folic
acid containing multivitamin tablets should contain on average not less than 90.0%
and not more than 150.0% of the label claim and the relative standard deviation
should be less than 6 %. The average percent per tablet (n=30) and the relative
standard deviation (RSD) were calculated as follows:
Percent average = (Average amount per tablet /Label claim)* 100
Relative Standard Deviation = (100 * Average amount per tablet)/ Standard deviation
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Table 11 contains the percent amount of folic acid per tablet (all tablets
labeled as containing 800 mcg, with the exception of NMV1 and NMV3 labeled as
1 mg) and the relative standard deviation for the tested products. All the products
tested passed the USP requirement for the content uniformity of folic acid in
multivitamins dosage units. It is of note that, while all products passed, five of the
products tested had a content > 120%. In theory this allows for a range of 9841230 mcg of folic acid in dosage units in this category.

Product
MV1*
MV 2*
MV 3*
MV 4*
MV 5*
NMV1**
NMV2**
NMV3**

Average Percent
105.5%
147.0%
130.1%
126.9%
123.2%
123.2%
104.3%
98.6%

RSD
4.9
3.0
3.0
1.6
1.6
3.6
3.0
3.5

Pass/Fail
Pass
Pass
Pass
Pass
Pass
Pass
Pass
Pass

* Multivitamin Tablet (Prenatal). ** Nephritic Multivitamin Dosage Unit.

Table 11. Average percent of folic acid in multivitamin dosage units.

Dissolution
Single entity folic acid tablets dissolution.
To meet the USP requirements for dissolution, not less than 75% of the
labeled amount of folic acid should be released in 45 minutes. Dissolution was
measured using USP apparatus II and test conditions specified under the folic acid
tablet monograph in USP 24. Unlike the USP requirement that the dissolution is to
be performed in distilled water, the measurement was performed in three different
media: simulated intestinal fluid (pH 1.5), distilled water (pH 5-6) and simulated
intestinal fluid (pH 7.5). Percent released was calculated as follows:
Percent released = (amount measured/label claim)* 100
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The amount measured/time point was from pooled samples of six products per
dissolution run (n=6).
All the tested products met the USP requirement of folic acid dissolution in
distilled water. More than 75% of the folic acid labeled amount was released in 45
minutes (Table 12). The dissolution range was 85%-143% (Figure 13). Of note is
the performance of product # 1; while it passed the dissolution test, it was the
slowest performing product, similar to its disintegration.
All the tested products released more than 75% of the labeled amount in 45
minutes in simulated intestinal fluid (Table 13). The dissolution profile of folic
acid in simulated intestinal fluid for each product was almost the same as the
dissolution profile obtained in distilled water (Figure 14). The dissolution range
was 89%-135%.
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Figure 13. Folic acid (in single entity folic acid tablets) dissolution profile in
distilled water.

.
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Product
1
2
3
4
5
6
7

Percent Released
(45 minutes)
85.7%
143.8%
93.5%
91.9%
106.3%
97.9%
97.4%

RSD

Pass/Fail

2.9
3.7
1.0
4.1
2.0
5.8
0.1

Pass
Pass
Pass
Pass
Pass
Pass
Pass

Table 12. Percent release of folic acid (in single entity folic acid tablets) in
distilled water

Product
1
2
3
4
5
6
7

Percent Released
(45 minutes)
89.7%
135.8%
112.3%
101.3%
101.5%
116.1%
110.1%

RSD

Pass/Fail

2.5
3.5
1.2
1.7
2.5
0.8
2.4

Pass
Pass
Pass
Pass
Pass
Pass
Pass

Table 13. Percent release of folic acid (in single entity folic acid tablets) in SIF.
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Figure 14. Folic acid (in single entity folic acid tablets) dissolution profile in SIF.
All the tested products failed to release 75 % of the labeled folic acid in 45
minutes in simulated gastric fluid (Table 14). Dissolution as low as 23% was
observed, where the highest percent released obtained for a product tested was
68% (Figure 15).

Product
1
2
3
4
5
6
7

Percent Released
(45 minutes)
23.6%
56.6%
38.0%
46.5%
51.9%
68.1%
34.1%

RSD

Pass/Fail

6.9
8.7
3.0
7.1
5.0
6.8
5.1

Fail
Fail
Fail
Fail
Fail
Fail
Fail

Table 14 . Percent release of folic acid (in single entity folic acid tablets) in SGF.
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Figure 15. Folic acid (in single entity folic acid tablets) dissolution profile in SGF.

In contrast with the disintegration results, these results demonstrate that the
dissolution of the folic acid tablets is sensitive to pH, with all products dissolution
rate being significantly diminished in the acidic conditions of SGF. The results of
the single entity folic acid tablet studies also suggest that degradation does not
contribute to product failure, as no significant degradation peaks were observed
during product assay.
Dissolution of folic acid in multivitamin dosage units.
This test is provided to determine compliance with the dissolution
requirements where stated in the individual class monographs for a tablet or
capsule dosage form. All nutritional supplements belonging to USP class II
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(water-soluble vitamins), class III (water-soluble vitamins with minerals), class IV
(oil- and water- soluble vitamins), class V (oil- and water- soluble vitamins with
minerals) and class VI (minerals), prepared as tablets or capsules are subject to the
dissolution test and criteria, described in the “Nutritional Supplements” chapter of
USP, for folic acid (43). This test is also required if the product labeling includes a
health claim concerning the relationship between folate deficiency and the risk of
neural tube defects.
To meet the USP requirements for dissolution of multivitamin dosage unit,
not less than 75% of the labeled amount of folic acid should be released in 60
minutes. Dissolution was measured using USP apparatus II for tablets or apparatus
I for capsules, and the test conditions specified under the folic acid USP 24
(disintegration and dissolution of nutritional supplements) (43). The measurement
was performed in three different media: simulated intestinal fluid (pH 1), distilled
water (pH 5-6) and simulated intestinal fluid (pH 7.5). Percent release was
calculated as follows:
Percent released = (amount measured/label claim)* 100
The amount measured/time point was from pooled samples of six products per
dissolution run (n=6).
Most of the tested products released more than 75% of folic acid in
distilled water in one hour. Only one of the products (NMW3) failed to pass the
USP requirement for folic acid dissolution in multivitamin dosage units. The

61

dissolution range was 38%-145% (Table 15).All the tested products except one
released more than 60% by 15 minutes (Figure 16).
Product
MV1*
MV 2*
MV 3*
MV 4*
MV 5*
NMV1**
NMV2**
NMV3**

Percent Release
100.6%
145.5%
106.1%
108.8%
112.4%
121.9%
102.5%
38.5 %

RSD
4.1
2.4
1.5
2.5
2.9
2.3
5.0
4.6

Pass/Fail
Pass
Pass
Pass
Pass
Pass
Pass
Pass
Fail
* Multivitamin Tablet (Prenatal). ** Nephritic Multivitamin Dosage Units.
Table 15. Percent release of folic acid (in multivitamin units) in distilled water in
60 minutes.
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Figure16. Folic acid (in multivitamin units) dissolution profile in distilled water.
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The tested products generated almost the same dissolution profile in simulated
intestinal fluid as those generated in distilled water. All products tested, except one (again
NMW3), passed the USP specification for folic acid in multivitamin dosage unit
dissolution. The dissolution range was 47%-130% (Table 16). Most of the tested products
released more than 60% by 15 minutes. However, the percent released from all the tested
products in 60 minutes was generally less than the percent released in distilled water
(Figure 17).
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Figure 17 . Folic acid (in multivitamin units) dissolution profile in SIF.
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Product
MV1*
MV 2*
MV 3*
MV 4*
MV 5*
NMV1**
NMV2**
NMV3**

Percent
Release
102.5%
130.2%
86.8%
99.5%
86.3%
85.9%
104.5%
47.4%

RSD

Pass/Fail

2.7
2.2
1.3
2.2
2.7
2.1
1.3
4.0

Pass
Pass
Pass
Pass
Pass
Pass
Pass
Fail

* Multivitamin Tablet (Prenatal). ** Nephritic Multivitamin Dosage Unitts

Table 16. Percent release of folic acid (in multivitamin units) in SIF in 60 minutes.

All the tested products failed to release 75% of folic acid in 60 minutes in
simulated gastric fluid (Table 17). The dissolution range was 15%-61%.
For some of the products tested the release plateaued after 45 minutes (Figure 18).

Product
MV1*
MV 2*
MV 3*
MV 4*
MV 5*
NMV1**
NMV2**
NMV3**

Percent
Release
61.2%
28.7%
52.9%
47.1%
45.8%
42.2%
32.8%
15.2%

RSD

Pass/Fail

2.7
4.2
1.7
1.5
3.0
2.4
1.7
4.3

Fail
Fail
Fail
Fail
Fail
Fail
Fail
Fail

* Multivitamin Tablet (Prenatal). ** Nephritic Multivitamin Dosage Unit.

Table 17. Percent release of folic acid (in multivitamin units) in SGF in 60 minutes.
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Figure 18 . Folic acid (in multivitamin units) dissolution profile in SGF.
In summary, the quality of commercially available folic acid products was
evaluated in terms of disintegration, content uniformity and dissolution. For each
test, at least one product failed to meet the USP specification for that test.
However, no single product failed to meet the USP requirements for all three tests
together.
Unlike USP requirements, disintegration and dissolution were also tested
in simulated gastric fluid and simulated intestinal fluid. With one exception, all
products tested passed dissolution in SIF. However, all the tested products failed
to release more than 75% of label claim within sixty minutes when placed in SGF.
This critical finding suggests a significant influence of acidic pH on product
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performance, which may be attributed, but not limited to, the pH-dependent
solubility of folic acid and/or the characteristics of the formulation excipients. This
limited dissolution in simulated gastric conditions also has physiological
relevance, since complete dissolution in the stomach would be preferred prior to
folic acid absorption in the upper small intestine. Finally, while the multivitamin
assay could not detect degradation products, single entity studies suggest that folic
acid degradation is not a major contributor to product failure.
III. Solubility of Folic Acid
Since the solubility of folic acid at acidic pH might play a major role in the
failure of the tested products to release more than 75% of label claim within sixty
minutes, the saturation solubility of folic acid at different pH values was
measured. A folic acid solubility-pH profile was generated (Table 18 and Figure
19). Folic acid exhibited an increased solubility with increasing pH at 37 °C. No
signs of major degradation of folic acid in the assigned pH values were observed.
Folic acid solutions were stable throughout the time course of the experiment (five
days). Folic acid solubility was relatively low in acidic fluid and significantly
higher in basic pH solutions. Solubility of folic acid at pH 10 was more than 100fold more than the solubility of folic acid at pH 1. Folic acid will be more highly
ionized in basic pH. The ionic form of folic acid is more soluble in aqueous
solutions than the non-ionic free acid form. This may be a contributing factor to
the distinct changes in dissolution as a function of pH for commercial folic acid
products.
pH
1
3
4
7
10

Folic acid solubility
(mg/ml)
0.029
0.840
1.050
5.330
19.47

RSD
4.02
1.66
5.33
0.77
2.84

Table 18 . Folic acid solubility in buffers at different pH.
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Figure 19. Folic acid solubility-pH profile.

IV. Dissolution of laboratory formulated folic acid products-Identification of
Failure Mechanisms
A. Standard excipients tablets.
To determine the contribution of folic acid tablet formulation to the
dissolution behavior of the test folic acid products, different folic acid
formulations were prepared in tablet dosage form. These tablets were tested for
weight variation, hardness and dissolution in simulated gastric fluid and simulated
intestinal fluid.
Table 19 contains the composition of each formulation, weight variation,
hardness test results, and amount released in simulated gastric fluid and simulated
intestinal fluid. First, folic acid was formulated in tablets containing only the
67

active ingredient and a filler as a base line. The two fillers chosen were methyl
cellulose and microcrystalline cellulose. Two lubricants, stearic acid and calcium
stearate, were then added to the formulation, each at a time and at two different
percentages, 1% and 5%, to test the effect of different lubricants and lubricant
percentage on the dissolution of folic acid. Lubricant levels can significantly affect
drug dissolution due to their hydrophobic nature. Finally, a croscarmellose was
added as a disintegrant to the formulation. These excipients constituted the most
common inactive ingredients in the tested commercial single entity folic acid
tablets.
Ingredients

M
M1
M2
M3
M4
M5
A
A1
A2
A3
A4
A5

MC + FA
MC + FA + Stearic Acid (1%)
MC + FA+ Stearic Acid (5%)
MC + FA+ Calcium Stearate (1%)
MC + FA +Calcium Stearate (5%)
MC + FA+ Calcium Stearate (1%)+
Croscarmellose (10%)
MCC+ FA
MCC+ FA + Stearic Acid (1%)
MCC + FA+ Stearic Acid (5%)
MCC + FA + Calcium Stearate (1%)
MCC + FA+ Calcium Stearate (5%)
MCC + FA+ Calcium Stearate (1%)+
Croscarmellose(10%)

Weight (g) ± CV
(n=18)

Hardness (Kp) ± SD
(n=6)

0.398±0.25

2.92±0.15

SGF
490.4

SIF
605.6

0.398±0.33

6.00±0.40

496.9

793.6

0.406±0.80

7.17±0.45

590.9

750.4

0.406±1.00

5.07±0.51

233.0

792.0

0.406±0.83

5.13±0.21

266.5

784.0

0.402±0.61

6.20±0.20

350.8

688.0

0.298±2.73

5.28±1.05

46.8

611.4

0.302±0.82

7.10±0.56

21.2

310.2

0.300±0.90

6.90±0.44

20.6

325.2

0.305±0.96

7.17±0.15

11.2

343.2

0.301±1.56

7.27±0.15

17.7

307.2

0.304±0.84

6.57±0.21

150.7

368.2

Amount Released
(mcg)
(60 minutes)

MC: Methyl Cellulose.
FA: Folic Acid.
MCC: Microcrystalline Cellulose.
Table 19 . Laboratory formulated folic acid tablets: composition, weight variation,
hardness, and dissolution in SGF and SIF.

All the formulated products with methyl cellulose released more than 75%
of the amount of folic acid in 60 minutes in simulated intestinal fluid (Figure 21).
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The addition of a lubricant or disintegrating agent did not affect the release. On the
other hand, only one of the tablets formulated with microcrystalline cellulose
released more than 75% of the amount of folic acid in 60 minutes in simulated
intestinal fluid. The addition of a lubricant lowered the release of folic acid in
simulated intestinal fluid (51%- 57% in 60 minutes); however, the addition of a
disinetgrant to the formulation improved the release of folic acid (Figure 22).
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Figure 20. Laboratory formulated folic acid tablets dissolution profile in SIF
All the formulated tablets failed to release more than 75% of the amount of
folic acid in 60 minutes in simulated gastric fluid (Table 19 and Figure 23).
Generally, the addition of a lubricant decreased folic acid release compared to the
baseline. Calcium stearate had a more pronounced effect on reducing the release
of folic acid than stearic acid. This likely is because calcium stearate has smaller
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particle size than stearic acid resulting in greater coating/surface coating
properties. The addition of a disintegrant improved the release of folic acid from
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Figure 21. Methyl cellulose laboratory formulated folic acid tablets dissolution
profile in SIF.
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Figure 22. Microcrystalline cellulose laboratory formulated folic acid tablets
dissolution profile in SIF.
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tablets containing 1% calcium stearate, which originally produced the lowest folic
acid dissolution profile( Figures 24 and 25). Most of the formulated folic acid
tablets with microcrystalline cellulose produced less than 10% release in 60
minutes in simulated gastric fluid. Methylcellulose, as a filler, provided better
product release than did microcrystalline cellulose (Figure 26). It appears that
certain excipients adversely affect folic acid dissolution, though, the acidic
conditions appear to be contributing factor.

80
M
M1
M2
M3
M4
M5
A
A1
A2
A3
A4
A5

Percent Released

60

40

20

0
0

10

20

30

40

50

60

Time(minutes)

Figure 23. Laboratory formulated folic acid tablets dissolution profile in SGF.
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Figure 24. Methyl cellulose laboratory formulated folic acid tablets dissolution
profile in SGF.
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Figure 25. Microcrystalline cellulose laboratory formulated folic acid tablets
dissolution profile in SGF.
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Figure 26. Comparison of fillers used in laboratory formulated folic acid tablets,
dissolution profile in SGF.
B. Buffered tablets.
According to the Nernst-Brunner equation (Equation 1), three variables
control the dissolution process. These three variables are the surface area of the
solid drug particles, the drug diffusional properties, and the saturation solubility of
the particular chemical form of the drug.
dQ/dt = (DS/h) (Cs-Cb) …………….. (1)
Q: amount of drug (gm)
T: time (sec)
D: diffusion coefficient of the drug (cm2/sec)
S: effective surface area of the drug particle (cm2)
h: thickness of the diffusion layer (cm)
Cs: saturation solubility of the drug in the diffusion layer (gm/ cm2)
Cb: concentration of drug in the bulk fluids (gm/ cm2)
The solubility of the drug in the diffusion layer surrounding the drug
particle has an important effect on the dissolution of the drug particle. If the drug
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has a low solubility in that layer, it will eventually produce a low dissolution rate
relative to conditions in which the drug’s solubility is higher. This may be a
contributing factor in the reduced rate of folic acid release in simulated gastric
fluid compared to simulated intestinal fluid. Folic acid has a pH dependent
solubility profile with inherent low solubility in acidic pH. In order to confirm
this, folic acid was formulated in two different formulations: one with methyl
cellulose and one in buffered tablets containing methyl cellulose and 25% citrate
buffer (sodium citrate and citric acid, 2:1). The tablets were fit in the die and the
die was hung in 500 ml of simulated gastric fluid. Only one surface of the tablet is
exposed to the medium, thus, dissolution occurs from a constant surface area
without mixing, which eliminates other variables that might affect the dissolution
process.
Normally, the pH of the bulk fluid may reflect the pH of the stationary
diffusion layer. However, in the case of buffered tablet, as the buffer dissolves, it
will alter the pH of the microenvironment of the stagnant diffusion layer to a pH
of ≈ 4, favoring more rapid dissolution of the active ingredient, without
significantly changing the pH of the bulk fluid (pH ≈1.5). Figure 27 shows the
amount of folic acid released from each of the formulated tablets (n=3). The
results indicated a significant difference (α = 0.05) between the average amount of
folic acid released from the buffered and non-buffered tablets. These findings
indicated a better folic acid release from buffered tablets (surface pH≈ 4) than nonbuffered(surface pH≈ 1.5), which supports the initial finding that the solubility of
folic acid is the rate limiting step in the dissolution process of folic acid in
simulated gastric fluid.
This conclusion can be achieved in another way. The dissolution rate is
determined by the difference between Cs and Cb, and not solely by Cs. The higher
the difference between Cs and Cb, the more rapid the dissolution rate. Sink
condition, which is achieved when the Cb/Cs ratio is less than 10%, should always
be maintained to drive the dissolution process.
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Figure 27. Constant surface area folic acid release.
In case of the buffered tablets, provided that the buffer increased the pH of
the diffusion layer to approximately pH 4 and hence increasing Cs by five-fold
compared to that at pH 1, the difference between Cs and Cb is greater than that
obtained when using non-buffered tablets and hence the dissolution rate is higher.
Also, with higher Cs at pH 4, a larger amount of drug can dissolve in the bulk (Cb)
before surpassing sink conditions (for further treatment of this data see Appendix
IV).
We hypothesize that increasing the buffer percentage in the tablet
formulation will produce a more pronounced effect on folic acid release; however,
the suppression of the folic acid peaks in the HPLC assay with an increasing the
buffer concentration did not allow the completion of these studies. An assay
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method that accounts for both the buffer and folic acid should be developed before
conducting such experiments.
The obtained results strongly indicate that there is a contribution of folic
acid solubility to its dissolution rate. However, one should also be aware of the
effect of other excipients in the formulation on the dissolution process, as
suggested by the variable dissolution profiles obtained with different excipients.
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Chapter V
Summary and Conclusions
Folic acid is a water-soluble vitamin that has been used to treat macrocytic
anemia without neurologic disease. Folate obtained from pharmaceutical
preparations is the most bioavailable, because 10% to 50% of dietary folate is lost
in the cooking process.
The vitamin folic acid has received considerable attention in the 1990s
because of its preventative role in birth defects and disease Significant literature
exists in the area of periconceptional use of the vitamin to decrease the risk of
neural tube defects (NTDs) such as spina bifida. It has also been suggested that
folic acid may be effective in decreasing certain risks of cardiovascular disease
and psychiatric illness, most notably dementia.
Nutraceuticals, which include folic acid, vitamins, and herbals, are
regulated by the FDA as foods not as drugs. A primary concern is the quality,
potency, and efficacy of nutritional supplements and label claims. Standards for
nutritional supplements were first proposed in the Pharmacopeial Forum in 1993
and accepted in 1995, though, manufacturers are recommended, but not required,
to follow those guidelines as long as the product is not labeled USP.
In the past, a number of commercially available folic acid products were
tested for compliance with USP monographs requirements for disintegration and
dissolution. A failure to meet USP requirements were observed in many of those
tested products and a release percent as low as 10% was also measured, raising
questions about the poor pharmaceutical quality of these products and the potential
impact on public health.
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In these studies, seven commercially available single entity folic acid
products and eight folic acid containing multivitamin products were tested for
disintegration, content uniformity and dissolution in three media: simulated gastric
fluid, distilled water and simulated intestinal fluid. One single entity folic acid
product failed to disintegrate completely in 30 minutes. Another single entity folic
acid product contained more than the USP allowed amount per tablet. One of the
folic acid containing multivitamin products failed to meet the USP specifications
for folic acid dissolution. All of the tested products failed to release more than
75% of the labeled amount in 60 minutes in simulated gastric fluid. The results of
the work showed that there appears to be great progress since the 1990’s in the
quality of commercially available folic acid products in meeting USP standards.
There was no significant difference in the pharmaceutical quality of the different
types of formulations studied (tablet vs capsule, multivitamin vs single entity).
Little folic acid degradation was noted in these products.
Nutrients, which include but are not limited to water soluble vitamins such
as folic acid, are absorbed by carrier-mediated membrane transport systems on the
brush-border, and basolateral membranes of the gut wall facilitate this. Most of
these carrier systems are present at the upper end of the small intestine. For folic
acid, most absorption occurs in the proximal jejunum. Thus, when taken on an
empty stomach, folic acid absorption may be altered since the gastric retention
time and the time to pass through the jejunum can be short. Folic acid absorption
is expected to be significantly reduced if it is not released from the dosage unit by
the time it passes through the folic acid absorption window in the proximal
jejunum. Thus, a fast and complete rate of folic acid dissolution in the stomach is
essential.
The USP dissolution test is a monitoring tool that helps predict the rate and
extent of drug release. For a drug or vitamin to be absorbed from the
gastrointestinal tract, it must first be released from the dosage unit in the stomach
before it passes through its absorption window in the proximal jejunum. It should
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be noted that complete release does not guarantee absorption, although it is an
essential provision for absorption to occur (The same is true for the relationship
between disintegration and dissolution). At present, specifications based on USP
dissolution apparatus I and II are the most widely used methods to assess the drug
release from a tablet or capsule. These standards are not ideal because the in vitro/
in vivo correlation for folic acid has not been established; failure to meet the
dissolution specifications does not allow one to state conclusively that
bioavailability of the product will be low. However, the guidelines are the best
available to ensure good absorption of vitamins from nutritional supplements.
All the products tested failed to release more than 75% of the labeled
amount in simulated gastric fluid in one hour. And since most of the folic acid
absorption occurs at the proximal jejunum, one can expect that, if the folic acid
tablet was taken on an empty stomach, most of the folic acid will pass its
absorption window in the tablet body as it will not be completely released into
solution for absorption. Therefore, a low extent of absorption from these folic acid
tablets is possible.
These findings are important for several reasons. First, the difference in
folic acid dissolution may significantly affect the adequacy of folic acid
supplementation to normal healthy women who may conceive. This will increase
the risk of neural tube defects, since protective blood folate levels might not be
achieved. Second, women with inborn errors of folate metabolism, as well as
individuals taking antiepileptic or other drug regimens that interfere with folic acid
production have special supplementation needs that may go unmet because of poor
dissolution levels, or excessive drug loading in these products, which could lead to
toxic effects.
Laboratory formulated folic acid tablets failed to release more than 75% in
60 minutes in simulated gastric fluid. Excipients used and tableting conditions also
had a significant effect on folic acid tablet dissolution. No sign of chemical
degradation of folic acid was observed throughout the studies. These finding
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suggested that the folic acid dissolution process is solubility controlled. Folic acid
has a pH dependent solubility profile with inherent low solubility in acidic pH.
This was confirmed by the result of constant surface area studies of folic acid
buffered and non-buffered tablets. The increased release of folic acid from the
buffered tablets compared to non buffered tablets demonstrated that the buffer’s
altered pH of the microenvironment of the stagnant diffusion layer led to a pH
favoring rapid dissolution of the active ingredient.
In conclusion, when formulating folic acid, its solubility should be taken
into consideration. Folic acid tablets should be designed in a way that ensure the
release of folic acid in acidic pH, so as it will be in solution and ready for
absorption as it passes through its absorption window in the proximal jejunum.
This can be achieved by formulating folic acid in buffed tablets, or by
complexation of folic acid with cyclodextrins to improve folic acid solubility in
acidic solutions. It should be noted if the USP changed the requirement for folic
acid dissolution medium to be simulated gastric fluid rather than distilled water,
the inherent low solubility of folic acid in acidic pH should be considered. Future
studies may include the construction of folic acid in vitro/ in vivo correlation using
liquid chromatography mass spectrometry techniques. The construction of this
correlation will have a great impact on optimizing folic acid formulation.
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Appendices

Appendix I: Representative Folic Acid HPLC Chromatograms.

Figure I. HPLC Chromatogram of folic acid (RT 12 min.) (0.2 mg/ml) and
methylparaben (RT 23 min.) (0.4 mg/ml) using HPLC assay method.
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Figure II. HPLC Chromatogram of folic acid (0.8 µg/ml) using HPLC assay for
single entity folic acid tablets.

Figure III. HPLC Chromatogram of folic acid (1.6 µg/ml) using HPLC assay of
folic acid in multivitamin dosage units.
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Appendix II: List of Commercial Drug Products Tested.

Product
Code

Product Name

Manufacturer

Lot No.

Folic Acid
(mcg)

1

Folic Acid

Naturally Preferred

306095

400

2

Folic Acid

Nature Made

LD11007N

400

3

Folic Acid

Rite Aid

39013

400

4

Folic Acid

Kroger

1HB0390

400

5

Folic Acid

Nature’s Bounty

52534 02

400

6

Folic Acid

PharmAssure

94505

400

7

Folic Acid

GNC

1394Dc2560

400

MV1*

Stuart Natal Plus 3

Integrity

210021

800

MV 2*

Stuart Natal

Integrity

205121

800

MV 3*

Prenatal

Eckerd

1KA0322

800

MV 4*

Prenatal Tablets

Rite Aid

94631

800

MV 5*

Prenatal Tablets

Kroger

1PBO541

800

NMV1**

Nephro-Vite

R & D Laboratory

0103

1000

NMV2**

Nephron FA

Nephro-Tech

307054

800

NMV3**

Nephrocaps

Fleming & Company
Fenton

6643004

1000
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Appendix III: Calculation of % dissolved in 45 or 60 minutes for
commercial products based on their actual (determined by content
uniformity), not labeled, amount.
Table I: Percent Release of folic acid (in single entity folic acid tablets) in 40
minutes..
Product Code
1
2
3
4
5
6
7

Percent Released (45 minutes)
SGF
DW
SIF
22.4%
81.2%
85.0%
40.1%
102.0%
96.3%
37.0%
91.0%
109.2%
45.4%
89.7%
98.8%
50.7%
103.9%
99.2%
67.2%
96.6%
114.6%
33.6%
96.0%
108.5%

Table II: Percent release of folic acid (in multivitamin dosage units) in 60 minutes
Product Code
MV1
MV2
MV3
MV4
MV5
NMV1
NMV2
NMV3

Percent Released (60 minutes)
SGF
DW
SIF
58.0%
95.4%
97.2%
19.5%
99.0%
88.6%
40.7%
106.1%
86.8%
37.1%
85.7%
78.4%
37.2%
91.2%
70.0%
34.3%
98.9%
69.7%
31.4%
98.3%
100.2%
15.4%
39.0%
48.1%

.* Multivitamin Tablet (Prenatal). ** Nephritic Multivitamin Dosage Unit.
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Appendix IV: Folic Acid Solubility- Analysis of Sink Conditions.
Table I: Commercial tested products (pH= 1.5/ Cs= 240 µg/ml).
Product

Percent Release

Amount Released
(ug/ml)

(Cg/Cs)%

(60 minutes)
MV1*

61.2%

MV 2*

28.7%

MV 3*

52.9%

MV 4*

47.1%

MV 5*

45.8%

NMV1**
NMV2**

42.2%
32.8%

NMV3**

15.2%

0.54

0.23

0.25

0.11

0.47

0.20

0.42

0.17

0.41

0.17

0.37

0.16

0.29

0.12

0.14

0.06

0.19

0.08

0.45

0.19

0.30

0.13

0.37

0.15

0.42

0.17

0.54

0.23

0.27

0.11

(45 minutes)
1

23.6%

2

56.6%

3

38.0%

4

46.5%

5

51.9%

6

68.1%

7

34.1%

From this analysis, it appears that sink conditions were maintained. This
suggests sensitivity not just of folic acid to pH conditions, but also of the
excipients which warrants further studied.
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Table II: Buffered vs Non-Buffered tablets (pH= 1.5/ Cs= 240 µg/ml // pH= 4.0/
Cs= 1.05 mg/ml).
Buffered Tablets (n=3)
(Cg/Cs)%
Time
0
15
30
45
60
75
90
120
180
240
300

Amount Released (µg)
pH=1*
pH=4
0
0
0
4.44
0.0037
0.0008
9.97
0.0083
0.0019
15.97
0.0133
0.0030
20.60
0.0172
0.0039
22.39
0.0187
0.0042
23.98
0.0200
0.0045
38.39
0.0320
0.0073
53.77
0.0448
0.0102
66.99
0.0558
0.0127
81.53
0.0679
0.0154
Non-Buffered Tablets (n=3)
(Cg/Cs)%

Time
0
15
30
45
60
75
90
120
180
240
300

Amount Released (µg)
0
7.36
17.33
23.09
29.59
45.19
41.45
51.14
71.05
84.56
92.71

pH=1
0
0.0061
0.0144
0.0192
0.0247
0.0377
0.0345
0.0426
0.0592
0.0705
0.0773

pH=4*
0
0.0014
0.0033
0.0044
0.0056
0.0085
0.0078
0.0097
0.0134
0.0160
0.0175

* The assumption is made that for the non-buffered tablets the pH at the surface is
1.5, and for the buffered tablets the pH at the surface is 4.0. From this comparison,
it shows that increasing the pH allows for better maintaining of sink conditions,
which is reflected in the increased dissolution rate of these products (Figure 27).
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